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1. Abstract 
 
The telomere repeat binding factor, TRF2, is a key component of the shelterin 
complex, which plays an important role in the maintenance of telomeres and the 
protection of the telomeric DNA from uncontrolled processing by the DNA 
damage machinery. Telomeres resemble double-stranded breaks (DSBs) and 
the shelterin complex hides the telomeres in a loop structure, called T-loop. 
Recent studies have suggested that TRF2 is able to bind and inhibit ATM, which 
scans the genomic DNA for DSBs. Therefore, TRF2 might be the key regulator of 
ATM at the telomeres. While TRF2 is abundant at the telomeres, it is possible 
that over-expression of TRF2 expands its ATM-inhibiting potential throughout the 
nucleus and therefore jeopardizes the DNA surveillance machinery elsewhere in 
the genome, which could give TRF2 oncogenic potential in vivo. To investigate 
this, it was the goal of my thesis to over-express TRF2 in the mouse 
hematopoietic system.  I delivered two variants of TRF2, transgenic mTRF2 and 
GFP-mTRF2, into mouse hematopoietic stem cells using lentiviral technology. 
The transduced cells were transplanted into C57BL/6J recipient mice and the 
successful integration of transgenic TRF2 was confirmed by genotyping. 
Functional over-expression of transgenic TRF2 in the hematopoietic system was 
verified by Western analysis and fluorescence microscopy. Pathological data and 
FACS analysis showed the development of CD4/CD8-double-positive T-cell 
lymphomas in a subset of TRF2 over-expressing mice but not in GFP-control 
mice. Surprisingly, over-expression of the TRF2 transgene was not detectable in 
tumor cells and a genomic screen did not show the presence of the TRF2 
transgene. I considered that TRF2 had oncogenic potential only in early stages of 
tumorigenesis and genome instability, which was detected by FISH analysis and 
the presence of anaphase bridges, explained the loss of the transgene in later 
stages of tumor development. However, the results of my thesis studies suggest 
that TRF2 does not act as a dominant oncogene in the mouse hematopoietic 
system. 
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2. Zusammenfassung 
 
Das Telomerprotein TRF2 ist ein Hauptbestandteil des Shelterin-Komplexes, 
welcher die Funktionsfähigkeit der Telomere und deren Schutz vor einem 
unkontrollierten nucleolytischen Angriffs des DNA Reparaturmechanismusses 
der Zelle sicherstellt. Telomere ähneln in ihrer Form Doppelstrang-Brüchen 
(DSBs), und der Shelterin-Komplex schützt die Telomere durch die Formation 
einer sogenannten T-loop Struktur. Neue Studien zeigen, dass TRF2 in der Lage 
ist ATM zu binden und dessen Funktion, nämlich die Suche nach DSBs innerhalb 
des Genoms, zu unterdrücken. Daher könnte TRF2 eine Schlüsselrolle in der 
Regulation von ATM an den Telomeren zukommen. Unter normalen Umständen 
ist TRF2 lediglich an den Telomeren in hoher Konzentration zu finden, jedoch 
könnte dessen Überproduktion die Unterdrückung von ATM auch andernorts der 
Telomere zur Folge haben. Somit würde der gesamte ATM-abhängige DNA 
Reparaturmechanismus in seiner Funktionalität beeinträchtigen. Im Zuge dessen 
würde TRF2 in vivo ein onkogenes Potential zu Teil. Um diese Hypothese zu 
untersuchen, war es das Ziel meiner Arbeit, TRF2 im murinen hematopoietischen 
System zu überproduzieren. Dazu habe ich zwei Varianten von TRF2, mTRF2 
und GFP-mTRF2, mittels lentiviraler Transduktion in murine hematopoietische 
Stammzellen eingeschleust. Die infizierten Zellen wurden in C57BL/6J 
Empfängermäuse transplantiert und die erfolgreiche Integration des Transgens 
wurde mittels Genotypisierung überprüft. Die funktionale Überproduktion von 
transgenem TRF2 im hematopoietischen System wurde mit Hilfe einer Western 
Analyse und Fluoreszenz Mikroskopie sichergestellt. Pathologische Befunde und 
FACS Analyse zeigten die Entstehung von CD4/CD8-doppel-positiven T-cell 
Lymphomen in einem Teil der TRF2 überproduzierenden Mäuse, nicht aber in 
den GFP-Kontrolmäusen. Überraschend war dabei, dass weder die 
Überproduktion von transgenem TRF2 in den Tumorzellen, noch die Präsenz 
des Transgens innerhalb des Genoms nachweisbar war. Daher zog ich es in 
Betracht, dass TRF2 sein onkogenes Potential nur in den frühen Stufen der 
Tumorbildung zeigt, und das genomische Instabilität, wie sie nachweisbar war 
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durch FISH Analyse und durch die Präsenz von Chromatid-Brücken in 
Anaphasen, zum Verlust des TRF2 Transgens in späteren Phasen der 
Tumorentwicklung führte. Die Ergebnisse meiner Arbeit lassen jedoch die 
Schlussfolgerung zu, dass TRF2 nicht als dominantes Onkogen im murinen 
hematopoietischen System wirkt. 
 
Keywords: 
TRF2, hematopoietic, oncogenic 
 
Schlagworte: 
TRF2, hematopoietisch, Onkogen 
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3. Introduction 
 
Circular genomes, as found in prokaryotes, can be fully replicated by 
conventional polymerases, while the presence of linear chromosomes, in 
mammals and other eukaryotes, presents a tremendous challenge to the 
replication process. Because cells divide and their genome needs to be 
replicated during each cell division, inevitably DNA is lost at the tip of the 
chromosomes due to the inability of conventional polymerases to replicate the 
linear ends of the chromosomes. This phenomenon has been characterized by 
Watson and Olovnikov as the so called “end replication problem” [1, 2], which 
results from the enzymatic activity of DNA polymerases that use a short RNA 
primer to initiate polymerization in the 5’-3’ direction. The DNA strands at the end 
of linear chromosomes are replicated in a different mode (Figure I - 1). For the 
replication of the one strand, termed the leading strand, a single primer can be 
continuously extended, presumably resulting in a blunt-ended molecule. The 
replication of the other strand, termed the lagging strand, requires a different 
mechanism of replication. Multiple short RNA primers are extended and the 
resulting Okazaki fragments are joined together after the removal of the RNA 
primers. While the internal gaps, which result from the removal of the RNA 
primers, can be filled in by polymerases, the gap at the very end of the replicated 
strand remains. It cannot be processed by any conventional polymerase and the 
replication of the lagging strand appears incomplete. With regard to the length of 
a RNA primer, each replication theoretically leads to a loss of 3 to 6 bp of DNA 
per end. But the actual loss is much larger in most organisms bearing linear 
chromosomes, as evidenced by the presence of single-stranded 3’ extensions of 
the G strand. Depending on the organism, overhang size can range from 12-16 
nucleotides in ciliates [3-5], around 30 nucleotides during S phase in S. 
cerevisiae [6, 7], and as long as 300 nucleotides in human cells [8]. Surprisingly, 
this overhang has been detected on both chromosome ends. Not only both 
termini of human chromosomes [8], but also those in Trypanosoma brucei [9], 
and Tetrahymena [10], end in an overhang estimated to be up to a few hundred 
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Figure I - 1 Schematic of replication at the very end of a chromosome 
 
Introduction  14 
nucleotides in length. While for the lagging strand this can be explained 
assuming that the RNA primer binds not at the very terminus of the actual 
chromosome tip, replication of the leading strand should theoretically result in a 
blunt end. However, this is not the case. The presence of an overhang suggests 
a nucleolytic process, which creates a single-stranded overhang in the case of 
the leading strand or extends the single-stranded overhang, in the case of the 
lagging strand. It is mandatory that generation of an overhang is counteracted to 
avoid the permanent loss of DNA with each cell division. 
In addition to preventing loss of the chromosome ends, organisms with linear 
chromosomes have to overcome the cellular response to DNA ends. Unprotected 
DNA ends resemble double-stranded breaks [11, 12], which are recognized and 
processed by the DNA damage machinery. It is necessary for the cell to 
eliminate chromosomal breaks that result from environmental stress, internal 
metabolism, DNA replication, and physiological breaks acquired during 
development. The solution is a mechanism that allows the cellular machinery to 
distinguish between common DNA breaks and the ends of linear chromosomes. 
Throughout evolution cells have developed a sophisticated complex, called the 
telomere, which allows higher organisms to overcome the loss of important DNA 
information during replication and to protect chromosomal ends from the cellular 
machinery. First defined as “free ends” that are unable to fuse with broken DNA 
[13], telomeres are complexes of repetitive DNA and associated proteins that can 
be found at all ends of linear chromosomes. 
 
3.1. Telomeric DNA sequences 
 
Telomeres were first characterized as long stretches of highly repetitive DNA in 
the ciliated protozoan Tetrahymena thermophilia. In this organism the ends of the 
linear DNA minichromosomes that comprise the amplified RNA genes (rDNAs) 
consist of approximately 50 tandem repeats of the hexanucleotide unit 
CCCCAA/GGGGTT, with the G-rich strand bearing the 3’-OH end of each end of 
the linear DNA [14]. The knowledge of telomere sequences in other organisms 
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expanded soon thereafter (Table I - 1), sharing an extremely simple, tandemly 
repeated DNA sequence containing a cluster of C residues [15]. Exceptions to 
these very conserved structures were discovered in K. lactis [16], where the 
telomeric repeats were expanded, and in S. cerevisiae and S. pombe with their 
irregular telomere repeats [17, 18]. In Drosophila melanogaster, these telomeres 
consist of repetitive sequences, which are actually retrotransposons of the non-
LTR type [19-21]. Although dipteran telomere structure and maintenance is 
unlike in any other organism, the telomeric functions are conserved. 
 
Table I - 1 Sequences of telomeric DNA in selected species. 1These are non-canonical 
since they are not maintained by telomerase. 
 
Telomeric sequence Species Reference 
TTGGGG Tetrahymena [14] 
TTTTGGGG Oxytricha, Euplotes [3] 
TTAGGG Trypanosoma brucei [22, 23] 
T(G)2-3(TG)1-6 Saccharomyces cerevisiae [17] 
GGTTACA Schizosaccharomyces pombe [18, 24] 
ACGGATTTGATTAGGTATGTGGTGT Kluyveromyces lactis [16] 
TTAGGC Caenorhabditis elegans [25] 
Het-A and TART retrotransposons1 Drosophila melanogaster [19-21] 
TTAGG Bombyx mori (silkworm) [26] 
TTTAGGG Arabidopsis thaliana [27] 
TTAGGG Homo sapiens and other 
vertebrates 
[28] 
 
 
Telomere length is highly variable among organisms. While in Tetrahymena and 
yeasts telomeric tracts are approximately 300 bp in length [14, 17], the TTAGGG 
repeats in human cells range from 2 kbp to 25 kbp [28-30]. Telomeres of up to 50 
kbp are found in some mouse species including the laboratory Mus musculus 
[31]. During each replication process part of the terminal tip of each chromosome 
gets lost so telomeres can act as a buffer to prevent the cell from loosing 
important genomic information, which is located in the more proximal area of the 
centromeres. Telomeres, however, only delay the end-replication problem and 
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for a single cell to overcome this problem and become immortal, it needs an 
active mechanism to maintain the length of the telomeric DNA over generations. 
 
3.2. Telomerase 
 
A cell can overcome extensive telomere shortening by the effective maintenance 
of the telomere length, which is accomplished by a widely employed mechanism, 
performed by the ribonucleoprotein telomerase. This protein contains two 
essential components, a telomerase reverse transcriptase catalytic subunit 
(TERT) [32] and a functional telomerase RNA (TR). While the RNA component 
serves as a template to align with the telomeric 3’-overhang, TERT synthesizes 
one repeat as specified by the RNA [33, 34]. Telomerase can then relocate to the 
newly synthesized telomeric end and repeat the process, or it continues the 
process at another DNA substrate. In general telomerase synthesizes the G 
strand first, followed by the C strand [35], with the result of a double-stranded 
repeat array. One possibility for the generation of the G strand overhang as it is 
found at chromosome ends could be by the abrogation of the process after the 
last G strand synthesis. This idea, however, is controversial since cells that lack 
telomerase activity can contain G-overhangs [8, 36-38]. A nucleolytic process is 
therefore a more likely explanation for the generation of the 3’-overhang. 
The G-overhang plays an important role in the maintenance of telomeric DNA. In 
vitro assays have shown that telomerase needs a single-stranded overhang to 
extend a DNA fragment, while blunt-ended DNA cannot be extended [39, 40]. 
Surprisingly, telomerase has a limited selectivity on the overhang. As shown, 
telomerase can elongate non-telomeric sequences both in vitro [39, 41-45] and in 
vivo [41, 46, 47]. This de novo addition of telomeric DNA is thought to be 
important for the “healing” function of telomerase, through which broken ends 
can be capped [48]. 
In unicellular organisms telomerase has a housekeeping function and its two 
essential subunits are always expressed. This expression level, however, can 
fluctuate and expression of telomerase RNA can increase at a specific
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development stage, for example during macronuclear development in 
Tetrahymena [49]. Telomerase activity is detectable in most mouse tissue [50], 
due to expression of both subunits of the enzyme [51-53]. The catalytic subunit of 
the mouse telomerase, in contrast to the RNA subunit, is haplo-insufficient so 
that cells heterozygous for mTERT gradually shorten their telomeres [54]. 
In most normal human tissue telomerase activity is repressed [55]. Activity is 
detectable only in ovaries and testis [56], and in highly proliferative tissues 
including hematopoietic cells [57, 58]. While the RNA subunit, hTR, is present in 
many telomerase negative cells, the regulation of telomerase appears to be at 
the level of hTERT expression. Telomerase activity is found in most of the 
primary tumors and tumor cell lines, showing the presence of mRNA of hTERT 
[59-61]. That hTERT regulates telomerase activity is further supported by the fact 
that the expression of hTERT alone in primary fibroblasts can establish 
telomerase activity [62, 63]. The fine balance between the suppression and the 
activation of telomerase activity needs to be further elucidated. To date, little is 
known about what leads to the suppression of telomerase in human somatic 
tissue and what causes its activation in 90% of human tumors [64]. 
 
3.3. Telomerase-associated proteins 
 
Telomerase activity cannot be constituted by the sole expression of the two 
subunits, hTR and hTERT. Biochemical and genetic studies suggest the 
existence of additional protein subunits of telomerase that may be involved in the 
assembly or biogenesis of active telomerase. These proteins may mediate or 
regulate the access of telomerase to its substrate, the telomeres (Table I - 2).  
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Table I - 2 Human telomerase-associated proteins. aa - amino acids; nt - nucleotides 
[65]. 
 
Protein Interacting region Function 
hTERT associated   
TEP1 aa 1-350, 601-927 Unknown 
P23/p90 aa 1-195 Assembly/conformation 
14-3-3 aa 1004-1132 Nuclear localization 
   
hTR associated   
TEP1 nt 1-871 Unknown 
hGAR1 hTR H/ACA domain Stability, maturation, localization 
Dyskerin/NAP57 hTR H/ACA domain Stability, maturation, localization 
hNOP10 hTR H/ACA domain Unknown 
hNHP2 hTR H/ACA domain Stability, maturation, localization 
C1/C2 nt 33-147 Stability, maturation, localization 
La nt 1-205, 250-451 Accessibility to telomeres? 
A1/UP1 nt 1-208 Unknown 
hStau nt 64-222 Accessibility to telomeres? 
L22 nt 64-222 hTR processing, localization? 
 
 
3.3.1. hTERT-associated proteins 
 
In previous studies in Tetrahymena thermophilia [66-68], the first protein to be 
found associated with telomerase activity is TEP1 (telomerase-associated protein 
1), which was subsequently identified in humans, mice, and rats [69, 70]. 
However, although association of TEP1 with the RNA and the catalytic subunit of 
telomerase had been shown [69, 71], the exact role of TEP1 in the context of 
telomerase has not been explained so far. Other proteins found to interact with 
telomeres are the chaperones p23 and p90 [72]. Both appear to be important for 
the functional assembly of the two basic subunits of telomerase since recent 
studies have shown stable association of both chaperones with the human 
telomerase [73]. The same studies suggest a role of p23 and p90 in the 
Introduction  19 
translocation process during telomere extension. Other proteins found to interact 
with hTERT are the 14-3-3 proteins [74]. While they are not required for the
activity in vitro or in intact cells, the results suggest that 14-3-3 proteins promote 
the nuclear localization of hTERT. 
 
3.3.2. hTR-associated proteins  
 
A number of proteins such as hGAR1, dyskerin/NAP57, hNOP10, and hNHP2 
[75-78] are found to interact with mammalian telomerase RNA by binding to the 
3’-terminal extension of the RNA subunit, which structurally resembles H/ACA 
snoRNAs [79, 80]. Small nucleolar ribonuclearprotein complexes (snoRNPs) [80] 
and some heterogeneous nuclear ribonucleoproteins (hnRNPs) [81-83] are also 
found to interact with hTR. SnoRNPs and hnRNPs appear to play a role in 
telomerase localization and also in telomerase accessibility to telomeres [83, 84]. 
Specifically, the La antigen interacts with hTR and telomerase and influences 
telomere length in vivo [85]. Finally, hStau and L22 interact with hTR and may 
play a role in hTR processing, localization and telomerase assembly [86]. The 
proteins mentioned above constitute a small portion of all that interact with hTR. 
The list of known telomerase-associated proteins is still growing, but their specific 
roles need to be further elucidated. 
 
3.4. Alternative ways of telomere lengthening 
 
While telomere length maintenance in most tumor cells is regulated by 
telomerase, another way of length control is termed “Alternative Lengthening of 
Telomeres”, or ALT [87]. The exact mechanism of ALT is not yet understood, but 
it is believed that a DNA strand from one telomere of an ALT cell anneals with 
the complementary strand of another telomere, thereby priming synthesis of new 
telomeric DNA using the complementary strand as a copy template [88]. The ALT 
pathway appears to be more dominant in cell lines and tumors of mesenchymal 
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origin than in those of epithelial origin [89]. Unlike cells where telomerase activity 
drives telomere maintenance and telomere length is very homogenous, ALT cells 
are characterized by the presence of a highly heterogeneous telomere pattern
(i.e. the telomere lengths range from very short to extremely long). Other data 
have shown that the coexistence of normal telomerase activity and the ALT 
mechanism in an individual tumor cell is a possibility [90-93]. It seems very likely 
that the cancerous and the normal cell lines that utilize ALT are subverting a 
normal mechanism, which is not discovered yet. Alternatively, other data suggest 
a dominance of telomerase over ALT, most likely because TERT may affect 
cellular functions in addition to telomere length and, although telomerase and 
ALT appear to be equivalent in their ability to immortalization, their contributions 
to tumor growth and survival in vivo may differ [94].  Finally, since inhibition of 
telomerase results in apoptosis or senescence [95-99], repression of the ALT 
mechanism also results in cell death or senescence [100, 101]. 
 
3.5. The telomere terminus 
 
As described previously, mammalian telomeres end with a 3’-overhang, 
composed of a several hundred nucleotide long stretch of the TTAGGG repeat.  
The overhang seems to play an important role in T-loop formation, a secondary 
structure of the telomeres I will describe later. Of all the possibilities that may 
explain the presence of the 3’-overhang, a 5’ to 3’ exonuclease or a combination 
of an endonuclease and a helicase are most likely needed to process telomere 
termini [8]. It has been further recognized that the 3’ nucleotide of the telomeres 
can represent each position within the TTAGGG repeat [102]. However, in the 
presence of telomerase, a prevalence of TAG-3’ ends was observed. In contrast, 
the 5’ end of a telomere is nearly always ATC-5’ [102]. 
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3.6. The T-loop 
 
Electron microscopic studies on purified human and mouse telomeres have 
revealed a secondary structure, termed the telomeric loop, or T-loop (Figure I - 2) 
[103]. The large duplex T-loop structures are formed by the invasion of the 3’-
overhang into the double-stranded part of the telomere. It is believed that T-loops 
hide the ends of the telomeres from the DNA damage machinery. The formation 
of the T-loop structure appears to be heavily dependent on the presence of 
telomere proteins, such as TRF1 and TRF2, because the T-loop resolves when it 
gets isolated and purified from proteins. 
 
 
 
 
 
Figure I - 2 Telomere structure.  Schematic of human telomeres in the "open" and T-loop 
states and (bottom left) electron microscopic micrograph of human telomeric DNA in the T-loop 
configuration in naked isolated DNA. 
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3.7. Shelterin   
 
In general three types of factors associate with telomeric DNA: nucleosomes, 
which obviously play a role in the chromatin structure of telomeres, some other 
chromosome transaction factors that also function elsewhere, and a six protein 
telomere core complex, recently termed shelterin [104]. To date little is known 
about the nucleosomes and chromosome transaction factors in the context of 
telomeres, although their role at the telomeres might be significant and will 
require further investigation. The role of the shelterin complex (Figure I - 3), 
however, appears to be essential for the functionality of telomeres. The shelterin 
complex is characterized by its high abundance at the telomeres throughout the 
cell cycle, but does not accumulate elsewhere since its function is limited to the 
telomeres. 
The first shelterin protein to be discovered was the mammalian telomere repeat 
binding factor, TRF1 [105, 106]. TRF1 showed in vitro binding specificity for 
double-stranded TTAGGG repeats. TRF2 was identified as a TRF1 paralog in 
genome databases [107, 108] and TIN2 and Rap1 were found in two-hybrid 
screens with TRF1 and TRF2, respectively [109, 110]. TPP1 [111-113] recently 
emerged from searches for TIN2-interacting proteins. POT1 appears to be the 
most conserved component of shelterin and was identified based on sequence 
homology to telomere end-binding factors in unicellular eukaryotes [114]. 
The cornerstone within the shelterin complex appears to be TIN2, which tethers 
TPP1/POT1 to TRF1 and TRF2. TIN2 also connects TRF1 to TRF2 and this link 
contributes to the stabilization of TRF2 on telomeres [112, 115]. Although 
subcomplexes of shelterin have been found [116], little about the number of 
shelterin units bound per telomere, the stochiometry of the shelterin subunits, is 
known. The shelterin complex affects the structure of telomeric DNA (Figure I - 
4). 
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Figure I - 3 Shelterin. (A) The six known subunits of shelterin, their domain structure, protein 
interactions, and DNA-binding sites. POT1 can bind its site both at a 3' end and at an internal 
position (as shown). Not shown is the interaction between POT1 and TRF2 reported by Harris 
and colleagues [117]. (B) Schematic of shelterin on telomeric DNA. For simplicity, POT1 is only 
shown as binding the site closest to the duplex telomeric DNA although it can also bind to the 3' 
end. (C) Potential shelterin complexes and subcomplexes on telomeres. (I) Six-subunit shelterin 
with POT1 not bound to ssDNA. (II) As in I, with POT1 interacting with TRF2. (III) The 
TRF2/Rap1/TIN2/TPP1/POT1 complex. (IV) The TRF1/TIN2/TPP1/POT1 complex. (V) The six-
subunit shelterin with POT1 bound to single-stranded telomeric DNA. The flexible linker between 
the POT1 DBD and the rest of the shelterin complex is speculative. Nucleosomes have been 
omitted from this and all other schematics of the telomeric chromatin [104]. 
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Figure I - 4 How shelterin may shape telomeres. (A) Generation of the telomere terminus. 
After replication, chromosome ends require processing in order to acquire a long 3' overhang. 
The nuclease involved is not known. The resulting 5' end always has the sequence ATC-5'. When 
POT1 is inhibited, this precision is lost. How POT1 determines the sequence of the 5' end is not 
known, but the resulting terminal structure is a preferred binding site for POT1 in vitro. (B) The T-
loop structure. The 3' overhang is strand-invaded into the adjacent duplex telomeric repeat array, 
forming a D-loop. The size of the loop is variable. (C) Speculative model for T-loop formation by 
shelterin. TRF1 has the ability to bend, loop, and pair telomeric DNA in vitro and could potentially 
fold the telomere. The shelterin component TRF2 can mediate T-loop formation in vitro. (D) 
Model for telomere length regulation by shelterin. As the T-loop is unlikely to be a substrate for 
telomerase, telomeres are only shown in the "open" state (either in a linear or in a more compact 
folded configuration) that could be generated during S phase. The presence of more shelterin on 
longer telomeres is proposed to increase the loading of POT1 on the telomeric overhang. POT1 
bound to the 3' end is proposed to block telomerase from acting. At the right, short telomeres with 
less shelterin are shown. Due to the diminished amount of shelterin, the chance that POT1 loads 
on the overhang is reduced, leading to a higher chance that telomerase can elongate the 
telomere. Forced increase of POT1 on telomeres (through shelterin over-expression) increases 
the chance that telomerase will be blocked, resulting in telomere shortening. Inhibition of 
shelterin, or a mutant of POT1 that does not bind ssDNA, reduces the chance that telomerase will 
be blocked, resulting in telomere elongation [104]. 
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It determines the structure of the telomere terminus, it is implicated in the 
generation of the T-loop, and it controls the synthesis of telomeric DNA by 
telomerase. As described in a later section, the shelterin complex appears to 
protect the telomeres from the DNA damage machinery. The following sections 
describe the characteristics of the six known shelterin subunits in more detail. 
 
3.7.1. TRF1 
 
TRF1 is a 439 amino-acid protein with three domains: an amino terminal acidic 
region, a dimerization domain, and a carboxy-terminal DNA-binding domain. The 
DNA-binding domain is an approximately 50 amino-acid region of the SANT/Myb-
type that is also structurally related to the homeodomain. The DNA-binding of 
TRF1 predominantly happens after dimerization of TRF1 [118, 119]. This 
dimerization is mediated by the TRF homology (TRFH) domain, a hallmark of the 
TRF family, which includes TRF2, S. pombe Taz1, and TRF from trypanosomes 
[108, 110, 119-121]. The linker region between the Myb domain and the TRFH 
domain appears to be flexible and diverges rapidly in mammalian evolution [120]. 
It has also been found that as a result of alternative splicing, hTRF1 molecules 
are expressed as two closely migrating proteins [122, 123], but they appear to be 
functionally identical. TRF1 can be found at the sites of telomeres throughout the 
cell cycle, including all stages of mitosis and meiosis [106, 108, 123-125].  The 
binding of TRF1 to the telomere sequence is highly specific and it has been 
shown that 5’-AGGGT-3’ is the core sequence required for TRF1 DNA-binding 
[126]. In vivo, where TRF1 is dimerized, the presence of two Myb domains 
increases the binding of TRF1 by tenfold. It is believed that the extreme spatial 
flexibility of dimerized TRF1 in vivo is due to the unstructured linker region in 
between the TRFH and Myb domain. 
TRF1 can act as a negative regulator of telomere length in telomerase-positive 
cells and, although diminished TRF1 loading on telomeres leads to telomere 
elongation, no telomere deprotection phenotype has been observed. However,
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TRF1 is essential in the mouse, suggesting that TRF1 contributes to the 
protection of telomeres [127]. 
 
3.7.2. TRF2 
 
TRF2 is a 500 amino-acid protein containing a TRFH domain and a short basic 
amino-terminal domain [108]. Although the structures of TRFH domains of TRF1 
and TRF2 are very similar, a steric clash prevents heterodimerization between 
both of them. TRF2 shows strong parallels to the TRF1 DNA-binding features. 
However, although this is true for sequence specificity and spatial flexibility, 
TRF2 has a greater tendency to form higher order oligomers and does not have 
telomeric DNA pairing activity [128]. In mice, TRF2 deficiency leads to early 
death during the embryogenesis [129]. The deletion of TRF2 results in p53-
dependent senescence, genome-wide chromosome end fusions, and a DNA 
damage response [129].  
Since my thesis was based on certain abilities of TRF2 in the context of DNA 
damage response, I will describe further characteristics of TRF2 in more detail 
later in the introduction. 
 
3.7.3. TIN2 
 
TIN2 is a small 354 amino-acid protein that binds the TRFH domain of TRF1 with 
its central region. This protein shows interaction with most shelterin subunits, 
including TRF1, TRF2, and TPP1, making it the cornerstone of the complex. 
TIN2 has also been shown to interact with POT1 through TPP1. Binding of TIN2 
to the telomeres is mediated by TRF1 and TRF2 [115, 130]. It has been 
suggested that the interaction of TRF1 and TRF2 through TIN2 enhances the 
binding affinity of both TRFs to telomeres. Disruption of the TRF1-TIN2-TRF2 
connection by a mutant version of TIN2 shows a telomere deprotection 
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phenotype [130]. It has also been shown that TIN2 acts to stabilize shelterin by 
protecting TRF1 from tankyrase 1 [131]. 
 
3.7.4. Rap1 
 
Human Rap1 is a 399 amino-acid protein with three domains: a BRCT domain, a 
single Myb domain, coiled region, and the Rap1 carboxy-terminal (RCT) domain. 
The RCT mediates the interaction with TRF2 as well as homotypic interactions. 
The Rap1 carboxyl terminus also contains a putative nuclear localization signal 
(NLS). Unlike Rap1 in budding yeast, which has diverged from human Rap1, the 
mammalian variant has only one Myb domain, which lacks the overall positive 
charges necessary to directly bind DNA [110]. The role of Rap1 within the 
shelterin complex is likely limited to the mediation of protein-protein interaction. It 
has also been shown that Rap1 levels at telomeres decrease in the absence of 
TRF2, similar to the Rap1 ortholog in S. pombe, which also localizes to the 
telomeres through a TRF2-like protein, Taz1p [132, 133]. Rap1 plays a role in 
telomere length regulation and affects telomere length heterogeneity [110, 134]. 
Furthermore, it was shown that mice lacking Rap1 are not viable, suggesting an 
important role of Rap1 in the protective activity of shelterin. 
 
3.7.5. TPP1 
  
TPP1 has been found as a component of shelterin by independent studies [111-
113]. The carboxy-terminal 60 amino-acids of TPP1 bind to the amino-terminal 
half of TIN2, and a central 100 amino-acid region in TPP1 binds to the carboxy-
terminus of POT1. Other than a serine-rich region separating these two 
interaction domains, the TPP1 sequence does not contain notable features. 
TPP1 appears to play a role in the recruitment of POT1 to telomeres and the 
inhibition of TPP1 consistently leads to inappropriate telomere elongation, a 
phenotype associated with diminished POT1 loading [112, 113]. Very recently 
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TPP1 has been demonstrated to be a putative mammalian homologue of TEBP-
beta in Oxytricha nova [135, 136]. 
 
3.7.6. POT1 
 
POT1 binds single-stranded DNA with two oligonucleotide/oligosaccharide-
binding (OB) folds [137]. It shows a high specificity for the sequence 5’-
(T)TAGGGTTAG-3’, which it can bind at the 3’ end or within a longer single-
stranded region [137, 138]. Studies suggest that POT1 can bind to the 3’-
overhang of telomeres over the full length of the single strand, but it prefers the 
most proximal and also the most terminal sequence of the 3’-overhang. The 
carboxy-terminal half of POT1, which binds to TPP1, is important for the 
localization of POT1 to telomeres, whereas the DNA-binding domain of POT1 is 
not. Recently it has been shown that two forms of POT1 emerge from alternative 
splicing: one full-length form and a shorter form that lacks the first of the two OB 
folds required for the single-stranded DNA-binding [138, 139]. The presence of 
the shorter POT1 variant is diminished and its function is not explored so far. 
Inhibition of human POT1 in primary cells leads to growth defects [140]. In 
addition, the mouse genome contains two variants of POT1, termed POT1a and 
POT1b. Although they are very similar in sequence and they both bind to 
telomeres, mice lacking POT1a die early in embryogenesis, indicating that these 
two versions of POT1 are not functionally redundant. In summary, POT1 plays a 
crucial role in telomere length control, acting as the terminal transducer. It also 
contributes to the protection of chromosome ends, since partial knock-down of 
POT1 results in a DNA damage response at telomeres, reduction in the single-
stranded telomeric DNA, changes in the 5’ end of the chromosome, and a mild 
telomere fusion phenotype [117, 139, 141]. 
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3.8. Non-shelterin telomeric proteins 
 
Numerous telomeric proteins that are not part of the shelterin complex have been 
found (Table I - 3). 
 
Table I - 3 Examples of non-shelterin proteins at human telomeres. Direct interactions 
with shelterin components are indicated where known. Factors recovered in association with 
shelterin are identified as such [104]. 
 
Protein complex Nontelomeric function Effects at telomeres Interactions 
Mre11/Rad50/Nbs1 recombinational repair DNA damage sensor 
T-loop formation/resolution? 
required for T-loop HR 
associated 
with shelterin 
ERCC1/XPF NER, crosslink repair 3' flap endonuclease 
deficiency leads to formation 
of TDMs; implicated in 
overhang processing after 
TRF2 loss 
associated 
with shelterin 
WRN helicase branch migration G4 DNA resolution 
deficiency results in loss of 
lagging-strand telomeres TRF2 
BLM helicases branch migration crossover repression T-loop formation/resolution? TRF2 
DNA-PK NHEJ deficiency leads to mild fusion phenotype 
associated 
with shelterin 
PARP-2 BER not known TRF2 
Tankyrases role in mitosis (tankyrase 1) 
positive regulator of telomere 
length through inhibition of 
TRF1 
TRF1 
Rad51D unknown (HR?) deficiency leads to mild fusion phenotype unknown 
 
 
Among those are the TRF1-interacting-ankyrin-related (ADP-ribose) 
polymerases, tankyrase 1 and 2 [142-144]. It is believed that tankyrases are 
negative regulators of TRF1 [142, 145], as over-expression of tankyrases 
removes TRF1 from the telomeres. This loss of TRF1 binding, however, can be 
counteracted by TIN2 [131].  
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Other important proteins with non-exclusive telomere functions are the WRN and 
BLM RecQ helicases. Recently it was shown that the WRN protein is involved in 
the resolution of G-quadruplex structures, which can be found in the lagging 
strand of the telomeres and need to be removed prior to the DNA replication 
process. Dysfunction of WRN by mutations in the RecQ-helicase domain leads to 
sudden sister telomere loss, called STL-phenotype [125]. The role of BLM at the 
telomeres has not been investigated yet, but interaction of BLM and TRF1 at the 
ALT-associated PML bodies (APBs) of ALT cells has been shown [146, 147]. 
RAD51D has also been detected at telomeres [148], most likely due to its role in 
homology-directed repair of double-stranded breaks (DSBs).  
A prominent marker for telomere dysfunction are chromosome end fusions, 
which take place between the C strand of one telomere and the G strand of 
another due to covalent end binding, also referred to as Non Homologous End 
Joining (NHEJ). I will describe the details of this process later (see below). 
The MRN complex, composed of Mre11, Rad50 and Nbs1, is recruited to the 
telomeres through an interaction with TRF2 [149]. While Mre11 and Rad50 are 
present at the telomeres throughout the cell cycle, Nbs1 is only detectable at 
telomeres in S phase. While the role of the MRN complex in mammalian cell 
function is important, its role at the telomeres needs to be further elucidated. 
However, it appears to act in the processing of unprotected telomeres, since 
there is an increase in MRN complex localization at unprotected telomeres. So 
far it has been shown that a mutant allele of Nbs1 induces telomere loss in some 
settings [150], and Nbs1 also contributes to the telomerase-mediated telomere 
elongation pathway [151]. 
 
3.9. Repression of the telomere-damage response by shelterin 
 
The structural influence of shelterin on the telomere complex allows the hiding of 
the 3’-overhang in the T-loop structure. Considering that the loss of the 3’-
overhang causes a DNA damage response, this would explain shelterin’s role in 
the inhibition of the DNA damage machinery at the sites of telomeres. However, 
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recent data show the induction of telomere damage foci even in the presence of 
the 3’-overhang [129], suggesting that shelterin has at least one other 
mechanism to prevent detection of telomeres by the DNA damage surveillance. It 
is therefore proposed that the T-loops created by shelterin result in nucleosomal 
organization, which conceals the chromosome ends from the DNA damage 
surveillance. In recent studies of ATM, 53BP1, and fission yeast Crb2 it was 
suggested that a key event in the DNA damage response is a change in the 
nucleosomal organization at the site of DNA damage [152, 153]. Formation of the 
T-loop structure, initiated by the shelterin complex, might constitutively hide 
methylated residues within the nucleosomes, which are necessary for 53BP1 to 
trigger the DNA damage machinery to the sites of damage. When the telomeres 
are exposed or if shelterin is inhibited, the telomeres and the nucleosomes are 
exposed and a 53BP1-dependent DNA damage response is initiated. However, it 
must be noted that this model of telomere end protection is still evolving and that 
other factors like the MRN complex and 9-1-1/RFC might also play a more crucial 
role in telomere damage signaling. Therefore, shelterin counter-tactics to 
telomere damage signaling need to be further investigated. 
 
3.10. The response to telomere attrition 
 
Telomere attrition in primary human cells results from the programmed 
shortening of human telomeres and limits their proliferation. When a telomere 
reaches a critical length, a cell cycle arrest is initiated, which has the hallmarks of 
a DNA damage response: DNA damage foci are detectable in (newly) senescent 
cells, the ATM kinase pathway is activated, and p53 enforces a G1/S arrest 
[154]. It appears that the shortest telomere, not the mean telomere length, 
triggers the induction of senescence. The effects of short telomeres are similar 
(or the same) to the cellular response to telomeres that lack shelterin. 
Dysfunctional mammalian telomeres are similar to DSBs and therefore their 
processing is similar: either by NHEJ or homologous recombination (HR). While 
NHEJ causes telomere fusions, formation of dicentric chromosomes, and the
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associated genome instability, HR can delete large segments of telomeric DNA 
and mediate exchange of sequences between sister telomeres. 
 
3.10.1. NHEJ 
 
A prominent phenotype of telomere dysfunction are chromosome end-to-end 
fusions. They can occur when telomeres are shortened, when shelterin 
components are inhibited, and upon loss of other telomere-associated proteins 
such as TRF2. As briefly mentioned before, these fusions are covalent 
connections between the C strand of one telomere and the G strand of another 
(Figure I - 5), and may occur before or after DNA replication. The resulting 
dicentric chromosome can become attached to both spindle poles and lead to a 
problem for chromosome segregation in anaphase. Consequently, in anaphase 
cells with dicentric chromosomes, characteristic chromatin bridges are observed. 
Factors involved in this process are DNA ligase IV and Ku70/80, DNA-PKcs and 
XRCC4. In general telomere fusions depend on the prior removal of the 3’-
overhang and the nucleotide excision repair factors ERCC1/XPF have been 
implicated in this process [155]. 
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Figure I - 5 Proposed role for shelterin in protecting telomeres from NHEJ and 
overhang loss. Telomeres are proposed to be resistant to NHEJ because of their T-loop 
configuration, which will block the NHEJ complex from accessing to the chromosome end. Upon 
loss of shelterin, T-loops are proposed to be destabilized (or not formed), allowing engagement of 
the NHEJ pathway. Prior to the ligation of chromosome ends by DNA ligase IV, the DNA-PK 
complex is proposed to form a synaptic structure that activates and/or recruits ERCC1/XPF. This 
nuclease is implicated in cleavage of the 3' overhang. End-joining of telomeres results in dicentric 
chromosomes (example shown at bottom). After DNA replication, fusions can occur between 
sister and non-sister telomeres. NHEJ can also occur prior to DNA replication, giving rise to 
chromosome-type fusions in metaphase (not shown) [104]. 
 
3.10.2. HR 
 
There are three types of HR that have detrimental outcomes at chromosome 
ends. The first is homologous recombination between sister telomeres, also 
called Telomere Sister Chromatid Exchange (T-SCE). It is crucial for a cell that 
the exchanged telomeres are equal in length to avoid lengthening of one sister 
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telomere at the expense of the other. In normal mouse and human cells, T-SCE 
is not very frequent, but ALT cells, which maintain their telomeres by a 
recombination pathway, have very frequent T-SCE [156-158]. Different levels of 
repression might be the reason for T-SCE in ALT versus normal cells. 
Telomeres are also threatened by a HR reaction referred to as T-loop HR [159]. 
T-loops are at risk for resolution by Holiday junction (HJ) resolvases because an 
HJ could be formed if the 5’ end of the telomere pairs with the displacement loop 
(D-loop). Branch migration in the direction of the centromere could generate a 
double HJ and resolution of the structure by crossover events would delete the 
whole loop segment, leaving a drastically shortened telomere at the chromosome 
end (Figure I - 6). Proteins involved in this process are the MRN complex and 
XRCC3, a Rad51 paralog associated with HJ resolution activity. Studies have 
shown that a mutant form of TRF2, which lacks the N-terminus, promotes T-loop 
HR, but further studies are necessary to characterize this process. However, it 
has been shown that the presence of telomeric circles, as they are found in ALT 
cells, lead to the further enhancement of this variant of HR [159, 160].  
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Figure I - 6 Control of T-loop HR by shelterin. Model depicting how late steps in HR can 
lead to sudden loss of telomeric DNA. Branch migration at the T-loop base can generate one or 
two HJs. Resolution of the double HJ in the direction shown will generate a shortened telomere 
and a circular telomeric DNA. T-loop HR is observed when an N-terminal truncation mutant of 
TRF2, lacking the basic domain, is over-expressed. The circular product of T-loop HR is also 
observed in ALT cells and at very low levels in unperturbed normal human cells. In ALT cells, the 
circles could provide a mechanism for telomere maintenance through rolling-circle replication 
[104]. 
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A third type of HR is the recombination between a telomere and interstitial 
telomeric DNA. While not common in human cells, mouse cells contain large 
stretches of telomeric sequences within their chromosomes. Recombination 
between telomeres and these elements could generate a terminal deletion, 
extrachromosomal fragments, inversions, and translocations. ERCC1/XPF might 
suppress this event since mouse cells lacking ERCC1 generate large 
extrachromosomal elements that contain a single stretch of telomeric DNA, 
presumably at a chromosome internal site [155]. 
 
3.11. The role of TRF2 in telomere protection and ATM inhibition 
 
Recent studies have shown that the shelterin subunit TRF2 has a weak 
interaction with the ATM kinase [161]. As a part of the shelterin complex, TRF2 is 
required to prevent mammalian telomeres from activating DNA damage 
checkpoints. Surprisingly, the results in this study show inhibitory effects on 
ATM’s ability to respond to DNA damage upon TRF2 over-expression. High 
levels of TRF2 abrogated the cell cycle arrest after ionizing radiation and 
diminished several other readouts of the DNA damage response, including 
phosphorylation of Nbs1, stabilization of p53, and upregulation of p53 targets. In 
response to TRF2 over-expression, the ATM autophosphorylation on S1981, an 
early step in the activation of this kinase, was inhibited. In vitro studies revealed 
that TRF2 binds to a region of ATM containing S1981, and ATM 
immunoprecipitates contained TRF2. We propose that TRF2 has the ability to 
inhibit ATM activation at telomeres. Strikingly, we found ATM localization to the 
sites of telomeres, mainly in S-phase and late G2 [162]. From this, and from the 
pure abundance of TRF2 at the telomeres but not elsewhere in the nucleus, we 
conclude that this mechanism of checkpoint control could specifically block a 
DNA damage response at telomeres without affecting the surveillance of 
chromosome internal damage. However, from this model we also predict that 
over-expression of TRF2 leads to a pure abundance of TRF2 elsewhere in the 
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nucleus. In a mouse model this could lead to suppression of checkpoints and 
therefore potentially to tumor formation (Figure I - 7). 
 
 
 
Figure I - 7 TRF2 over-expression in mouse hematopoietic stem cells might cause 
genome instability and tumor development. (A) Normal levels of TRF2 protein are sufficient to 
suppress telomeres from signaling as DNA double-stranded breaks (DSB) by suppressing the 
ATM dependent DNA damage machinery. DSBs elsewhere in the genome are not affected by the 
inhibitory effect of TRF2 on ATM. Normal checkpoint activation can occur, followed by either DSB 
repair or apoptosis. (B) Over-expression of TRF2 leads to the abundance of TRF2 throughout the 
nucleus, which might expend the inhibitory effect of TRF2 to genomic regions other than the 
telomeres and potentially suppresses checkpoint activation, resulting in genome instability and 
eventual tumor development. 
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In this thesis I focused on the over-expression of TRF2 in a mouse model. With 
respect to previous in vitro results, I predicted TRF2’s potential to act as an 
oncogene in vivo. First, I will describe the design of the vector system for the 
TRF2 transgene and the method I used to transduce hematopoietic bone marrow 
stem cells with my vector constructs. Next, I will show how I characterized the 
primary recipient mice in regard to the transgene. I will then study the effects of 
TRF2 over-expression on tumor development by macroscopical observations 
and how its over-expression is affecting the differentiation pattern of 
hematopoietic stem cells. Additionally, I will show data regarding over-expression 
of the TRF2 pattern in observed tumors. Finally, I will look into genome instability 
of tumors from mice over-expressing TRF2. 
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4. Methods and Material 
 
4.1. Cell culture 
 
Primary cells. Human fibroblasts HeLa 1.2.11 and mouse fibroblast-like 3T3 cells 
were obtained from ATCC. Cells were grown in 1x DMEM supplemented with 
10% (v/v) FBS, 0.1 mM non-essential amino acids, 100 units/ml Penicillin and 0.1 
mg/ml Streptomycin. 
Cells were passaged by treatment with trypsin and seeded at 5x105 cells per 10 
cm dish. Cell numbers were determined by counting a 1:20 dilution of the cell 
suspension using a Coulter Counter. For storage in a -80 oC liquid nitrogen 
freezer, cells were collected from a 15 cm plate (approximately 7x106 cells), 
resuspended in 1 ml of 2xA freezing media (40 ml FBS, 0.4 ml gentamycin stock 
solution (stock solution is 50 mg/ml gentamycin (Sigma) and filtered through a 
0.2 µm filter). Subsequently, 1 ml of 2xD freezing media was added (40 ml PVP 
stock solution (stock solution is 100 mg/ml PVP (Sigma) prepared in HEPES 
buffered saline), 30 ml DMSO (Sigma) 4 ml HEPES stock solution (stock solution 
is 1 M HEPES (pH 7.6)), and 126 ml L15 media (Sigma) and filtered through a 
0.2 µm filter) and the cell suspension was aliquoted into two cryogenic vials. The 
vials were placed in a Cryo 1 C Freezing Container (NALGENE) at –80 oC for at 
least one day, but not longer than 3 month, and subsequently transferred to liquid 
nitrogen. 
 
4.2. Lentiviral vectors 
 
Standard techniques were used for cloning. TRF2 constructs were generated by 
PCR from a full-length cDNA clone (clone #1639). The p156RRLsinPPTCAG-
EGFP-PRE(masa) vector (a gift from the Verma lab, The Salk Institute) was used 
to generate the GFP-mTRF2 expression vector. The same version without GFP 
was used to generate the mTRF2 expression vector. The GFP-control construct, 
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p156RRLsinPPTmCMV-GFP-PRE, was a gift from Nien Hoong, The Salk 
Institute.  
4.3. Lentiviral plasmid isolation 
 
Lentiviral vectors were transformed into E. coli TOP10 bacteria cells (Invitrogen) 
using standard molecular techniques. Cells were grown in 500 ml of LB broth 
Miller media (EMD) supplemented with 50 µg/ml Ampicillin at 37 oC and 230 rpm. 
Cell suspensions were centrifuged in 750 ml buckets for 10 minutes at 5000 rpm 
(Sorvall RT7). The bacteria were resuspended in 40 ml of Solution I (1% (v/v) 
Glucose, 25 mM Tris (pH 8), 10 mM EDTA in ddH2O) and placed on ice. 80 ml of 
Solution II (0.2 M NaOH, 1% (w/v) SDS in ddH2O) was added to the resuspended 
cells, mixed by gentle inversion, and incubated on ice for 5 minutes. Next, 60 ml 
of cold Solution III (3 M Potassium Acetate, 1 M Glacial acetic acid) were added, 
first mixed gently by inversion and then more vigorously, and incubated for 10 
minutes on ice. Suspensions were centrifuged for 30 minutes at 4000 rpm at 4 oC 
(Beckman J-6B). The supernatant was poured through a funnel lined with layered 
gauze pads to filter out protein debris. Then 100 ml of cold isopropanol were 
added to the supernatant, mixed by inversion, and placed on ice for 10 minutes, 
before centrifuging for 20 minutes at 8000 rpm (J2-21 Beckman), the supernatant 
was poured off and the pellet was drained upside down on a paper towel, then 
resuspended in 8.5 ml of 10 mM Tris pH 7.5/1 mM EDTA total volume. 8.8 g 
CsCl was added and mixed until dissolved, when 300 µl of ethidium bromide 
stock (10 mg/ml) (Pierce) was added. The mixture was loaded in Vti 90 tubes 
(Beckman) and centrifuged over night at 60000 rpm at room temperature 
(Beckman L8-80M Ultracentrifuge). The resulting band was pulled out using a 
22-gauge needle and a syringe and transferred to a 15 ml tube. The ethidium 
bromide was removed by extraction with about 4 ml of isopropanol/CsCl until the 
DNA was no longer pink. The plasmid DNA was precipitated by adding two 
original volumes of TE (10 mM Tris pH 8/1 mM EDTA pH 8) and three original 
volumes of isopropanol. The mixture was vortexed and incubated for 5 minutes 
at room temperature, then subsequently centrifuged for 10 minutes at 3000 rpm 
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at room temperature, and the supernatant was then discarded. The plasmid DNA 
was dissolved in 400 µl of TE, 5 µl of RNAse A stock (20 mg/ml) added, and 
incubated for 30 minutes at 37 oC. After Phenol/Chloroform extraction, the 
plasmid DNA was precipitated by adding 20 µl of 3 M Sodium acetate and 800 µl 
ethanol. The suspension was incubated for 1 minute and centrifuged for 10 
minutes at maximum speed in a table centrifuge. After a final ethanol wash, the 
plasmid DNA was resuspended in 400 µl TE. 
 
4.4. Transfection of primary cells 
 
Cells were transfected using Lipofectamine 2000 (Invitrogen) as described in the 
distributors manual. Briefly, one day before transfection, cells were plated at 
1x106 cells in 500 µl of 1x DMEM supplemented with 10% (v/v) FBS and 0.1 mM 
non-essential amino acids so cells reach 90 to 95% confluence at the time of 
transfection. The plasmid DNA was diluted into 50 µl of Opti-MEM I Reduced 
Serum Medium without Serum and gently mixed. In parallel, Lipofectamine 2000 
was diluted in 50 µl Opti-MEM I Medium and incubated for 5 minutes at room 
temperature. Then plasmid/lipofectamine mixtures were combined, gently mixed 
and incubated for 20 minutes at room temperature. 100 µl of the solution were 
aliquoted to the well containing cells and medium and mixed gently. Cells were 
incubated over night at 37 oC, when the medium was replaced by fresh medium 
containing antibiotics. Cells were further processed for Western analysis and 
immunofluorescence after 48 hours, as described (4.12 and 4.13). 
 
4.5. Lentivirus production 
 
293T cells were plated on one 15 cm plate and grown in 1x DMEM 
supplemented with 10% (v/v) FBS, 0.1 mM non-essential amino acids, 100 
units/ml Penicillin and 0.1 mg/ml Streptomycin and grown to confluence. Cells 
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were trypsinized and split into twelve 15 cm plates coated with poly-L-lysine 
(Sigma). 293T cells were transfected when cells reached approximately 70% 
confluence. The three packing plasmids and lentiviral vector containing the 
transgene were mixed in a 50 ml tube. For twelve 15 cm dishes the DNA 
transfection cocktail contained 95 µg of pVSVG, 68 µg of pREV, 176 µg pMDL, 
and 270 µg transgenic lentiviral vector. The CaCl2 was mixed well with the 
plasmid preparation to a final concentration of 0.25 M. Subsequently, an equal 
volume of 2x BBS solution was added to the calcium-DNA mixture, followed by 
gentle mixing. The mixture was incubated for 10 minutes at room temperature 
and a volume of 2.25 ml was added dropwise to each 15 cm plate and cells were 
incubated over night at 3% CO2 at 37 oC. The medium was changed 12 to 16 
hours post transfection. The plates were further incubated at 10% CO2 at 37 oC. 
Virus containing media was harvested at 24 h and 48 h intervals post-
transfection. Every sample was immediately filtered through a 0.22 µm cellulose 
acetate filter and stored at 4 oC. The collected medium was loaded into 
ultracentrifuge tubes (Beckman) and centrifuged in a SW28 rotor for 2 hours at 
19400 rpm (Beckman L8-80M ultracentrifuge) at room temperature. The 
supernatant was poured off and tubes were kept inverted. Recalcitrant medium 
drops were aspirated from the tubes. The pellet was resuspended in 1 ml HBSS 
(8 g/l NaCl, 0.4 g/l KCl, 60 mg/l KH2PO4, 47.9 mg/l Na2HPO4, 1 g/l Glucose, 0.35 
g/l NaHCO3), and the tube was washed twice with 500 µl each. The collections 
were pooled and loaded on top of 1.5 ml of phosphate-buffered 20% (w/v) 
sucrose into small ultracentrifuge tubes (Beckman). Tubes were then centrifuged 
in the SW55 rotor for 2 hours at 21000 rpm in a L8-80M ultracentrifuge 
(Beckman) at room temperature. Supernatant was removed and pellet 
resuspended in two steps of 100 µl each in a final volume of 200 µl in HBSS. The 
virus suspension was vortexed for 1 to 2 h at low speed at room temperature, 
quick-spun in microcentrifuge for 2 seconds and the supernatant was aliquoted in 
20 µl aliquots and stored at -80 oC. 1 µl of concentrated viral supernatant was 
mixed with 89 µl 1x PBS (pH 7.4) (8.2 g/l NaCl, 0.2 g/l KCl, 1.7 g/l 
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Na2HPO4*7xH2O, 0.2 g/l KH2PO4) + 10 µl 5% Triton from the p24 ELISA kit 
(Perkin-Elmer) and stored at -20 oC. 
 
4.6. Mice 
 
B6.SJL-Ptprca Pep3b/BoyJ mice (The Jackson Laboratory) were used to isolate 
bone marrow positive for CD45.1. TgN(beta-act-EGFP) mice [163] (a gift from 
the Verma lab, The Salk Institute) were used to isolate GFP-positive donor bone 
marrow. C57BL/6J (The Jackson Laboratory) were chosen as recipient mice. 
 
4.7. Isolation of bone marrow 
 
For the generation of the Primary #1 population, bone marrow was isolated from 
15 male B6.SJL-Ptprca Pep3b/BoyJ (CD45.1 donor) and 5 male TgN(beta-act-
EGFP) (GFP donor). For the generation of the Primary #2 population, bone 
marrow was isolated from 20 male B6.SJL-Ptprca Pep3b/BoyJ (CD45.1 donor). 
The mice were sacrificed by cerebral dislocation, and the femur and tibia were 
placed into 1x PBS/2 % (v/v) BIT9500 (StemCell Technologies). To isolate the 
bone marrow, the femur and tibia were ground by mortar and pestle. The 
suspension was filtered through a Cell Strainer (BD Falcon), and then centrifuged 
for 10 minutes at 700 x g. The pellet was resuspended in 1x PBS and cell 
numbers were determined by counting a 1:20 dilution of the suspension using a 
Coulter Counter. Suspensions were diluted to 5x107 cells/ml. To enrich 
hematopoietic stem cells, cell suspensions were separated using the StemStepTM 
cell separation system (StemCell Technologies) as directed. The cell numbers of 
the enriched hematopoietic stem cells were determined as described above and 
resuspended in Myelocult M5300 (StemCell Technologies). 
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4.8. Infection of bone marrow 
 
Sorted bone marrow cells were diluted to approximately 1.2x107 to 1.4x107 
cells/ml in Myelocult M5300 medium and 200 µl virus were mixed with the cells in 
both primary experiments, Primary #1 and Primary #2. The suspension was 
incubated at 37 oC over night and in the following morning the suspension was 
washed once with 1x HBSS, centrifuged for 5 minutes at 400 x g, and 
resuspended in 1x HBSS. 
 
4.9. Transplantation of bone marrow 
 
Prior to transplantation, recipient C57BL/6J mice were irradiated with 11 Gy and 
deeply anesthetized. Each mouse received lateral tail vein injections of 300 µl 1x 
HBSS containing 100.000 to 200.000 cells. During the first two weeks post 
transplantation all mice were maintained on Baytril water (Bayer Health Care). All 
mice were stored in the Biohazard suite at the Salk Institute’s Animal Facility 
throughout the course of the experiment. 
 
4.10. Genotyping of primary and secondary recipient mice 
 
Genomic DNA from blood and tissue samples of C57BL/6J mice as well as HeLa 
1.2.11 expressing GFP-mTRF2 cells was isolated using the DNeasy tissue kit 
(Qiagen). DNA was resolved from the column using 50 µl prewarmed TE. Nested 
PCR was performed by PCR using the outer PCR primer pair (mTRF2 Outer F1: 
5’-GCA GAT TGC TGT TGG AGG AGG-3’; WPRE R1: 5’-GCC ACA ACT CCT 
CAT AAA GAG ACA G-3’), generating a 626 bp PCR-product, followed by PCR 
using the inner PCR primer pair (mTRF2 Inner F1: 5’-ATG TCA GCA TCC AAG 
CCC AGA G-3’; mTRF2 Inner R1: 5’-CCA GTT TCC TTC CCC GTA TTT G-3’), 
generating a 252 bp PCR-product. For details on PCR-mixture and PCR-program 
see Table M - 1. 
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Table M - 1 PCR-mixture and -program for genotyping. (A) PCR-mixture for outer and 
inner PCR. * = 1 µl of unpurified PCR-product of the outer PCR was used as a template for the 
inner PCR. (B) PCR-program for the outer and inner PCR. 
 
A. Outer PCR    Inner PCR   
  µl Final [c]   µl Final [c] 
 DNA 2 -  DNA 2 - 
 10x PCR Buffer 2.5 1x  10x PCR Buffer 2.5 1x 
 MgCl2 2.5 2.5 mM  MgCl2 2.5 2.5 mM 
 Primer 1 0.25 0.5 µM  Primer 1 0.25 0.5 µM 
 Primer 2 0.25 0.5 µM  Primer 2 0.25 0.5 µM 
 Taq-polymerase 0.2 1 U  Taq-polymerase 0.2 1 U 
 dNTP 0.5 0.2 mM  dNTP 0.5 0.2 mM 
 ddH2O 16.8   ddH2O 17.8  
  25 µl    25 µl  
 
B. Outer PCR    Inner PCR   
 1’ 95 oC   1’ 95 oC  
 30‘’ 58 oC   30‘’ 60 oC  
 45‘’ 72 oC 35 cycles  30‘’ 72 oC 35 cycles 
 30’’ 95 oC   30’’ 95 oC  
 5’ 72 oC   5’ 72 oC  
 Hold 4 oC   Hold 4 oC  
 
  
Integration of the transgene into the hematopoietic system of primary recipient 
mice was verified by nested PCR and the PCR-product was separated on a 1.3% 
(w/v) Agarose gel and visualized by Ethidum Bromide (EtBr) (Pierce) under UV 
light. The gel was blotted onto a Hybond-N+ nitrocellulose membrane, 
(Amersham) followed by standard Southern analysis procedures. The cDNA of 
mTRF2, which was initially used as a template for the generation of TRF2 
lentivectors, served as a probe for the TRF2 transgene and was radioactively 
labeled with 32γ−dCTP. The membrane was stored in a Phosphorimager cassette 
(Amersham) and the exposed screen was analyzed on a Typhoon 8600 imager 
(Molecular Dynamics). 
Genomic DNA isolated from tumor tissue samples was screened in a one-step 
PCR using the outer primer pair, generating a 626 bp PCR-product. The PCR-
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product was separated on a 1.3% (w/v) Agarose gel and visualized by EtBr under 
UV-light. No Southern analysis was performed with these samples. 
 
4.11. Protein isolation 
 
Primary cells were washed with 1x PBS on plate and trypsinized using 2.5% (v/v) 
Trypsin/EDTA. Cell numbers were determined by counting a 1:20 dilution of the 
cell suspension using a Coulter Counter. Subsequently, cells were centrifuged for 
5 minutes at 1000 rpm and washed twice in 1x PBS. The cell pellet was 
resuspended at a dilution of 10000 cells/µl in 4x NuPAGE LDS sample buffer 
(Invitrogen). 
Tissue samples of spleen were mashed through a 70 µm Cell Strainer (BD 
Falcon) in the presence of 1x PBS/2% (v/v) FCS. Cell numbers were determined 
by counting a 1:20 dilution of the cell suspension using a Coulter Counter.  The 
cell suspension was then centrifuged for 5 minutes at 1000 rpm and washed 
twice in 1x PBS. The cell pellet was resuspended at a dilution of 10000 cells/µl in 
4x NuPAGE LDS sample buffer (Invitrogen). 
 
4.12. Western analysis 
  
Whole cell extracts of primary cells or protein extracts from tissue samples and 
resuspended in 4x NuPAGE LDS sample buffer (Invitrogen) were separated on 
3-8% (w/v) Tris-Acetate gradient gels (Invitrogen) and transferred to 
nitrocellulose by electroblotting for 80 minutes at 30 V at 4 oC. Membranes were 
stained with 20 mg/ml Ponceau S in ddH2O (Sigma) for 2 minutes to verify 
transfer. Blocking and incubation with primary (incubation for either 4 hours at 
room temperature or over night at 4 oC) and secondary antibodies (incubation for 
45 minutes at room temperature) was performed in 5% (w/v) milk and 0.1% (v/v) 
Tween in 1x PBS. Primary antibodies were as follows: rabbit-anti-mTRF2 #6889 
(1/1000, Karlseder lab), mouse-anti-γ-Tubulin GTU-88 (1/10000, Sigma), rabbit-
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anti-ATM Protein Kinase pS1981 (1/500, Rockland), rabbit-anti-p53 pS15 
(1/1000, Santa Cruz), mouse-anti-GFP (1/200, Chemicon International). After 
incubation with secondary antibodies (1/5000, Amersham), all blots were 
developed using the ECL kit (Amersham). 
 
4.13. Immunofluorescence on cultured cells, bone marrow and 
 spleen 
 
Mouse fibroblast-like 3T3 and human fibroblast HeLa 1.2.11 cells were grown in 
a 10 cm plate on microscope cover slips (Fisherbrand). Bone marrow and spleen 
suspension from C57BL/6J mice were attached to microscope slides by loading 
200 µl of cell suspension into cytofunnels (Thermo Electron Corporation) and 
centrifugation in a Shandon Cytospin 4 Cytocentrifuge (Thermo Scientific) for 10 
minutes at 800 rpm. Coverslips and microscope slides were rinsed in 1x PBS, 
fixed in phosphate-buffered 4% (v/v) formaldehyde for 10 minutes at room 
temperature, washed twice in 1x PBS for 5 minutes each, and blocked and 
permeabilized with 0.1% (v/v) Triton-X 100, 5% normal goat serum (Vector) and 
1% (w/v) BSA in 1x PBS for at least 30 minutes. All antibody incubation steps 
were carried out in a darkened humidified chamber at room temperature. 
Antibodies were diluted in 0.1% (v/v) Triton-X 100, 5% normal goat serum, 
(Vector) and 1% (w/v) BSA in 1x PBS. The first antibody incubation was for 2 
hours, followed by three wash steps with 1x PBS for 5 minutes each. Primary 
antibodies were as follows: rabbit-anti-mTRF1 #6888 (1/500, Karlseder lab), 
rabbit-anti-mTRF2 #6889 (1/500, Karlseder lab), mouse-anti-TRF2 (1/500, 
upstate biotechnology). The secondary antibody incubation was for 45 minutes, 
followed by three wash steps with 1x PBS. Secondary antibodies were as 
follows: donkey-anti-rabbit-FITC (1/200, Jackson), donkey-anti-mouse-FITC 
(1/200, Jackson), donkey-anti-rabbit-TRITC (1/200, Jackson). DAPI (4’, 6’-
diamidino-2-phenylindole) was added to the final wash steps for a final dilution of 
1/10000. Microscope slides and cover slips were then embedded upside-down in 
ProLong Gold (Molecular Probes) and sealed with nail polish. Pictures were 
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taken on an Axioplan2 Zeiss microscope with a Hamamatsu digital camera 
supported by OpenLab software. 
 
4.14. Immunofluorescence on microtome sections 
 
Tissue sections of mice were isolated and fixed in phosphate-buffered 4% (v/v) 
formaldehyde for one day, then transferred to 30% (w/v) phosphate-buffered 
sucrose. The tissues were prepared as free-floating freezing microtome sections 
(40 µm) and stored at in tissue cryo-protection solution (TCS) at -20 oC until time 
of immunofluorescence preparation. Tissues were removed from TCS and 
washed in TBS pH 7.6 (6.1 g/l Trizma base, 9 g/l NaCl) for three times and then 
blocked for 1 hour (3% (v/v) FCS in TBS with 0.25% (v/v) Triton-X 100). Tissues 
incubated with the first antibody, rabbit-anti-ATM Protein Kinase pS1981 (1/500, 
Rockland), were incubated over night at 4 oC. Next morning, tissues were rinsed 
in TBS two times, 15 minutes each, and rinsed in 3% (v/v) FCS in TBS with 
0.25% (v/v) Triton-X 100 for 15 minutes. The tissues were incubated with the 
second antibody, goat-anti-rabbit-TRITC (1/200, Jackson), in 3% (v/v) FCS in 
TBS with 0.25% (v/v) Triton-X 100 for 1 to 2 hours, followed by three wash steps 
with TBS. To counterstain, tissues were incubated in a 1/30000 dilution of DAPI 
in TBS for 5 minutes. Tissues were mounted on a coverslip using Dabco/PVA, 
dried over night at 4 oC in the dark, and sealed with nail polish. Pictures were 
taken on a Leica TCS SP2 AOBS and analyzed by LCS Lite software. 
 
4.15. Flow cytometry 
 
Flow cytometric analysis was used to determine differentiation patterns in sorted 
GFP-negative and GFP-positive bone marrow, and to determine transgene 
expression in developed tumors from transplanted C57BL/6J mice. Flow 
cytometry was also applied for the analysis of the Annexin V apoptosis assay. To 
detect CD45.1 donor bone marrow, aliquots of bone marrow cells and 
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thymocytes were stained with anti-mouse CD45.1 antibody (A20) conjugated to 
R-Phycoerythrin (R-PE). If mice were transplanted with GFP donor bone marrow, 
a GFP signal was used to evaluate the presence of donor bone marrow. Cell 
suspensions were also stained with 7-Amino-Actinomycin D (7-AAD, BD 
Biosciences) to determine the cells viability. Lineage analysis was performed by 
double staining using anti-mouse CD45.1 R-PE antibody with each of the 
following antibodies conjugated to either allophycocyanine (APC) for GR-1 (Ly-
6G), CD3ε (145-2C11), CD4 (RM4-5.B), CD11b (M1/70), CD19 (1D3), CD34 
(RAM34), or a goat-anti-mouse secondary antibody conjugated to AF-350 to 
detect Mac-1 (WT.5) and CD8 (53-6.7). All primary antibodies were purchased 
from BD Biosciences, and the secondary antibody was purchased from 
Molecular Probes. Flow cytometric analysis was performed on a LSR I 3-laser 6-
color analytical flow cytometer (Becton-Dickinson) and data were analyzed using 
the CellQuest software (Becton-Dickinson). 
 
4.16. Cell sorting for colony forming assay (CFA) and liquid assay 
 
Bone marrow cells harvested from a CD45.1 donor bone marrow transplanted 
mouse were separated into GFP-positive and GFP-negative pools using the 
FACS Vantage SE DiVa (Becton-Dickinson). 
For the CFA, 24000 cells were resuspended in 12 ml MethoCult GF3434 
(StemCell Technologies) and divided into six 35 mm miniplates. 2000 cells were 
seeded per plate and incubated for three weeks at 37 oC. Colonies were counted 
and characterized using light microcopy and the presence of the GFP signal was 
evaluated by fluorescence microscopy. 
For the liquid culture 2000 cells were plated in the cavity of a 24-well plate in 
M5300 medium (StemCell Technologies) supplemented with the cytokines IL-3 
and IL-6 (StemCell Technologies) and SCF (StemCell Technologies) at 100 ng/µl 
each. Differentiation patterns were analyzed by flow cytometry after two weeks of 
incubation at 37 oC. 
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4.17. Annexin V apoptosis assay 
 
Mice were irradiated at 5 Gy and thymus and spleen were isolated after 4 hours. 
The thymus was mashed through a 70 µm cell strainer (BD Falcon) in the 
presence of 1x PBS/2% (v/v) FCS. The thymocyte suspension was stored on ice 
until further processed. The spleen was isolated and flash freezed in liquid 
nitrogen until further prepared for confocal microscopy. Thymocyte numbers 
were determined by counting a 1:20 dilution of the suspension using a Coulter 
Counter. Roughly 300000 thymocytes were filled into a 15 ml Falcon tube and 
their volume was adjusted to 5 ml with 1x PBS. The suspension was centrifuged 
for 5 minutes at 4000 rpm at room temperature, the supernatant was removed 
and the pellet was washed once in 5 ml 1x PBS, centrifuged for 5 minutes at 
4000 rpm, and the pellet was resuspended in 300 µl Annexin V binding buffer (10 
mM HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2). The 
Annexin V AF-647 antibody (Molecular Probes) was added to the suspension at 
a dilution of 1/100 and mixed. The mixture was incubated on ice for 15 minutes 
and then analyzed by flow cytometry. 
 
4.18. Pathological observations 
 
Tissue samples of mice were fixed in 4% (v/v) p-formaldehyde for one day, 
subsequently transferred to phosphate-buffered 30% (w/v) sucrose and stored at 
4 oC in the dark. Pathological studies were carried out at the Department of 
Pathology, UC Davis. 
 
4.19. Peptide nucleic acid (PNA) fluorescence in-situ hybridization 
 (FISH) on metaphase spreads 
 
FISH was performed essentially as described [164] with minor modifications. 
Intact spleen was flushed with 1x PBS/2% (v/v) FCS using a syringe attached 
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with a 25-gauge needle and suspended splenocytes subsequently were 
centrifuged at 1000 rpm for 5 minutes. Splenocytes were then resuspended in 
200 µl 1x PBS/2% (v/v) FCS and transferred into one well of a 24-Well plate. 
Splenocytes were supplemented with 3 ml 1x DMEM with 10% (v/v) FCS, 0.1 
mM non-essential amino acids, 100 units/ml Penicillin and 0.1 mg/ml 
Streptomycin, and 0.1 µg/ml colcemid. The splenocyte suspension was 
incubated at 37 oC for 90 minutes, transferred to a 15 ml conical falcon tube, and 
the volume was brought to 15 ml with 1x PBS. This sample was again 
centrifuged at 1000 rpm for 5 minutes. The supernatant was completely removed 
and splenocytes were resuspended in 5 ml 0.075 M KCl, prewarmed to 37 oC. 
For exactly 7 minutes the cells were incubated at 37 oC, with occasional 
inversion to mix. The suspension was once more centrifuged at 1000 rpm for 5 
minutes and the supernatant was decanted, leaving roughly 200 µl of KCl on top 
of cells. The splenocytes were resuspended in the remaining KCl by gently 
tapping the tube. While vortexing at full speed, drop-by-drop 500 µl of 
methanol:glacial acetic acid (3:1) were added, followed by an additional 500 µl. 
Added more quickly. Finally, the suspension was filled to 10 ml with methanol: 
glacial acetic acid (3:1) and stored at 4 oC over night. 
Fixed splenocytes were spun at 1000 rpm for 5 minutes to remove most of the 
supernatant and the splenocytes were resuspended in the remaining volume of 
approximately 500 µl by gently tapping the tube. The slides were incubated in 
methanol:glacial acetic acid (3:1) and transferred to cold ddH2O prior to 
metaphase spread preparation. Splenocytes were dropped on water-wetted 
slides from about 1 m distance, let dry a couple of seconds, and washed with 
fresh fixative with Pasteur pipette from the edge of the microscope slide. The 
slides were then placed on a humidified heatblock at 80 oC for 3 minutes. Slides 
were stored over night at room temperature. 
Metaphase spreads were fixed in phosphate-buffered 4% (v/v) formaldehyde for 
2 minutes, washed in 1x PBS three times for 5 minutes each and then treated 
with pepsin (2 mg/ml) (Sigma) in acidified water (pH 2) at 37 oC for 10 minutes. 
The fixed cells were washed twice in 1x PBS for 2 minutes, fixed again in 
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phosphate-buffered 4% (v/v) formaldehyde, washed three times in 1x PBS for 5 
minutes each, and then dehydrated in an ethanol series (5 minutes in 70% (v/v) 
ethanol, 5 minutes in 95% (v/v) ethanol, and five minutes in 100% (v/v) ethanol) 
and air-dried. A small amount (50 – 100 µl of hybridization mix (10 mM Tris (pH 
7.2), 70% (v/v) deionized formamide, 0.5% (v/v) blocking solution (Boehringer 
Mannheim), 0.5 µg Peptide-Nucleic Acid (PNA) probe per ml (FITC-
CCCTAACCCTAACCCTAA, synthesized by Applied Biosystems) was placed on 
the slide. A glass coverslip was placed on top of the slide with hybridization mix. 
The cellular DNA was denatured by placing the slide at 80 oC for 3 minutes on a 
heatblock, and the probe was allowed to hybridize for 2 hours at room 
temperature in a darkened humidified chamber. Subsequently, the slide was 
washed two times, 15 minutes each in 10 mM Tris (pH 7.2), 70% (v/v) deionized 
formamide, 0.1% (w/v) BSA, and washed three times 5 minutes each in 0.1 M 
Tris-HCl (pH 7.4), 0.15 M NaCl, 0.08% (v/v) Tween. To the final washing step 
DAPI was added to a final dilution of 1/10000. Finally, the slides were dehydrated 
in an ethanol series as described above, air-dried, and the slides were then 
embedded in ProLong Gold (Molecular Probes), covered by microscope cover 
slides and sealed with nail polish. Pictures were taken on Axioplan2 Zeiss 
microscope with a Hamamatsu digital camera supported by OpenLab software. 
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5. Results 
 
5.1. Experimental overview of the over-expression of   
 recombinant mTRF2 in C57BL/6J mice 
 
Over the course of the project I performed a series of experiments to investigate 
the possible oncogenic activity of TRF2 in vivo. At this point I would like to give 
an overview (Figure 1). It shows how primary and secondary mouse colonies 
were generated, which type of donor bone marrow was used for the transduction 
and transplantation, and how I planned to follow up tumor development in 
transplanted mice. 
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Figure 1 Experimental setup for the over-expression of recombinant mTRF2 in the 
hematopoietic system of C57BL/6J mice. Primary recipients for transgenic mTRF2, GFP-
mTRF2 and GFP were generated in two independent experiments, termed Primary #1 and 
Primary #2. To increase chances of tumor-development, bone marrow from selected primary 
recipients was transplanted into secondary recipient mice, termed Secondary #1 and Secondary 
#2. If tumor-development occurred in either population, selected specimens were further 
investigated applying Immunofluorescence, Genotyping, Western analysis, Flow cytometry, 
and/or pathological analysis.  
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5.2. Functional over-expression of recombinant mTRF2 and 
 GFP-mTRF2 in vitro 
 
Two vector constructs were designed for the over-expression of recombinant 
mouse TRF2 (mTRF2) in the hematopoetic system of C57BL/6J mice (4.2). To 
verify the functional expression of both recombinant proteins, mTRF2 and GFP-
mTRF2, I transfected 3T3 cells with both constructs. The localization of 
recombinant TRF2 to telomeres is considered a sufficient indicator for functional 
expression. 
Western analysis confirmed over-expression of both recombinant proteins, which 
were successfully detected at the expected size of 66 kDa for mTRF2 and 94 
kDa for GFP-mTRF2 (Figure 2). 
 
 
 
 
 
Figure 2 Recombinant mTRF2 and GFP-mTRF2 was over-expressed in 3T3 cells by 
transfection. Endogenous TRF2, recombinant mTRF2, and recombinant GFP-mTRF2 were 
detected using an antibody specific for TRF2. γ-Tubulin was used as a loading control. 
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Functional expression of both recombinant proteins was shown by 
immunofluorescence (Figure 3). The telomere repeat binding factor, TRF1, was a 
positive control for telomere localization. In control 3T3 cells, endogenous TRF1 
and TRF2 colocalize and show distinct foci within the nucleus. After their 
transient transfection into 3T3 cells, telomeric localization for both recombinant 
proteins was detected, evidenced by their colocalization with endogenous TRF1 
at the telomeres. Thus, both recombinant proteins are functionally over-
expressed in vitro. 
 
 
 
 
Figure 3 Functional expression of transgenic mTRF2 in 3T3 cells displayed by 
immunofluorescence. (A) Untransfected 3T3 control cells stained for endogenous TRF1 and 
TRF2. (B) Over-expressed GFP-mTRF2 and (C) mTRF2 do colocalize with endogenous TRF1. 
Chromatin was counterstained with DAPI. White arrows indicate colocalization of TRF1 with (A) 
endogenous and (B+C) over-expressed (GFP-)mTRF2. Immunofluorescence, 63x1.25. 
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5.3. Production and quantitative verification of lentivirus batches 
 
The lentiviral backbone of the two constructs was used to produce virus batches. 
Each viral titer was verified by a p24 ELISA assay, which detects the presence of 
viral particles. For the mTRF2 construct I measured a virus titer of 3x109 
particles/ml, for GFP-mTRF2 8.5x109 particles/ml. Both virus batches were then 
used to infect bone marrow and to generate the “Primary #1” colony. In an effort 
to improve the viral titer and to increase the viral infection efficiency, I attempted 
to optimize the virus production and produced another virus batch. I included in 
this second virus production a virus based on a GFP-control construct, in addition 
to the two TRF2 constructs. I again quantified all three viruses by a p24 ELISA. 
Although I attempted to improve the virus titer, the second virus production was 
in fact less efficient than the first production based on the p24 ELISA results. For 
the mTRF2 construct I measured a virus titer of 8.2x107 particles/ml, for GFP-
mTRF2 6.4x108 particles/ml and for GFP-control 3.8x109 particles/ml. Despite 
having a low virus titer, all three batches were subsequently used for the 
generation of the “Primary #2” colony. 
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5.4. Transduction and transplantation of bone marrow into  
 primary C57BL/6J recipient mice 
 
In the course of the project I generated two primary C57BL/6J recipient mouse 
colonies (Figure 4). In the first round I transplanted a total of 32 C57BL/6J 
recipient mice (Primary #1). 13 mice received GFP donor bone marrow 
transduced with mTRF2 and 19 mice received CD45.1 donor bone marrow 
transduced with GFP-mTRF2. In the second round I used the optimized virus 
batches of recombinant mTRF2, GFP-mTRF2 and GFP-control to infect CD45.1 
donor bone marrow. The infected bone marrow was then transplanted in a 
second round of primary transplantations into a total of 53 C57BL/6J recipient 
mice (Primary #2). 19 mice received CD45.1 donor bone marrow transduced with 
mTRF2, 17 mice received CD45.1 donor bone marrow transduced with GFP-
mTRF2, and as a control I transduced CD45.1 donor bone marrow with a GFP-
control lentivirus and transplanted it into 17 C57BL/6J recipient mice. Both 
primary colonies were subsequently monitored for tumor development over time. 
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Figure 4 Generation of primary recipient mice by lentiviral transduction of 
transgenic TRF2 into GFP and CD45.1 donor bone marrow. (A) Primary #1 colonies were 
generated by the transduction of GFP donor bone marrow with the mTRF2 transgene and 
CD45.1 donor bone marrow with the GFP-mTRF2 transgene. (B) For the Primary #2 colony only 
CD45.1 donor bone marrow was used and transduced with a GFP-control, the mTRF2 and the 
GFP-mTRF2 transgene. Recipient mice were always C57BL/6J. 
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5.5. Functional over-expression of the mTRF2 transgene in  
 CD45.1 donor bone marrow 
 
After showing functional over-expression of recombinant mTRF2 in vitro, I was 
interested to see if this functionality was also present in transduced CD45.1 
donor bone marrow. Therefore, I infected CD45.1 bone marrow with the 
produced lentivirus for GFP-mTRF2 and mTRF2. After 10 days in culture I could 
detect over-expression of both transgenes in the bone marrow (Figure 5).  
 
 
 
 
Figure 5 Over-expression of recombinant (GFP-)mTRF2 in bone marrow cells 
isolated from CD45.1 donor mice. Endogenous and recombinant (GFP-)TRF2 was detected by 
a TRF2 specific antibody. 
 
 
Functional expression of GFP-mTRF2 in bone marrow could also be shown by 
immunofluorescence. As a positive control for telomere localization I stained 
again for endogenous TRF1. As seen in 3T3 cells, recombinant GFP-mTRF2 
colocalized with endogenous TRF1 (Figure 6). Thus, recombinant mTRF2 was 
functionally expressed in CD45.1 donor bone marrow. 
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Figure 6 Functional expression of recombinant GFP-mTRF2 in CD45.1 donor bone 
marrow cells. GFP-mTRF2 was visualized by the GFP-tag and TRF1 was detected by a TRF1 
specific antibody. Chromatin was counterstained with DAPI. White arrows indicate colocalization 
of endogenous TRF1 with recombinant GFP-mTRF2. Immunofluorescence, 63x1.25. 
 
 
5.6. Detection of virus integration into the hematopoietic system 
 of C57BL/6J primary recipient mice by nested PCR and 
 Southern analysis 
 
Successful integration of transgenic TRF2 into the hematopoietic system of 
recipient mice was confirmed by nested PCR followed by Southern analysis. I 
isolated genomic DNA from blood of all primary transplanted mice. A specifically 
designed primer pair (Figure 7) was used to detect the integration of transgenic 
mTRF2 and GFP-mTRF2 by nested PCR. The amplified PCR product was then 
analyzed by Southern analysis to verify its sequence specificity (Figure 8). Based 
on the Southern analysis, 26 out of 32 mice (Primary #1) and 15 out of 36 mice 
(Primary #2), respectively, showed the integration of either transgenic mTRF2 or 
GFP-mTRF2 into their hematopoietic system. As expected, in mice that received 
bone marrow transduced with a GFP-control transgene, transgenic mTRF2 was 
not detectable. 
Taken together, these results show the successful integration of transgenic 
mTRF2 and GFP-mTRF2 into the hematopoietic system of primary C57BL/6J 
recipient mice. 
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Figure 7 Schematic of primer binding in the nested PCR. (A) Only transgenic TRF2 will 
generate a PCR-product in the first step of the PCR. This template can be used in the second 
step to generate the final PCR-product. (B) The DNA of endogenous TRF2 cannot be used as a 
template and will therefore not lead to a final PCR-product. 
 
 
 
Figure 8 Genotyping of primary recipient mice transduced with transgenic (GFP-) 
mTRF2 and GFP by nested PCR and subsequent Southern analysis. (A) Results for the 
Primary #1 and (B) Primary #2 colony. As a genome negative control ('Mock'), genomic DNA from 
a C57BL/6J mouse was used. As a positive PCR control (+), genomic DNA of GFP-mTRF2 
expressing HeLa cells was included. ddH2O was used as a PCR negative control (-). 
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5.7. Transplantation of bone marrow from primary recipients into 
 secondary C57BL/6J recipient mice 
 
To further promote tumor progression in recipient mice, I transplanted bone 
marrow from primary recipient mice that was successfully transduced with 
transgenic TRF2 (Figure 9). To do this, I isolated primary bone marrow from the 
Primary #1 colony and transplanted it into irradiated C57BL/6J secondary 
recipients. A total of seven secondary recipient populations were generated: two 
populations received bone marrow transduced with mTRF2, another two 
populations received bone marrow transduced with GFP-mTRF2, and the 
negative control received bone marrow transduced with a GFP-control 
transgene. Depending on the time of transplantation, I subdivided all secondary 
recipient populations into Secondary #1 and Secondary #2. As with the primary 
colonies, I monitored the secondary populations for tumor development. 
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Figure 9 Transplantation of bone marrow from primary recipient mice into 
secondary recipient mice. (A) A total of four secondary populations for mTRF2 and GFP-
mTRF2 were generated. Each secondary population received bone marrow from one individual 
Primary #1 donor, either CD45.1 donor bone marrow over-expressing GFP-mTRF2 or GFP donor 
bone marrow over-expressing mTRF2. (B) For the GFP-control transgene a total of three 
secondary populations, each from one individual Primary #2 donor, expressing the GFP-control 
protein in CD45.1 donor bone marrow, were generated. All recipient mice were C57BL/6J. 
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5.8. Functional over-expression of transgenic mTRF2 in the 
 hematopoietic system of C57BL/6J mice 
 
Once I was able to show that transgenic TRF2 can be functionally over-
expressed in vitro, I investigated functional over-expression of the transgene in 
recipient mice in vivo. As shown by immunofluorescence studies in Figure 10, I 
could detect expression of the TRF2 transgene in bone marrow of a secondary 
recipient mouse. Again, I used endogenous TRF1 as a marker for telomeres. I 
observed colocalization of TRF1 and recombinant TRF2, in bone marrow and 
spleen, which confirmed that transgenic TRF2 is functionally expressed in 
C57BL/6J recipient mice. 
 
 
 
 
Figure 10 Transgenic GFP-mTRF2 is functionally expressed in the hematopoietic 
system of recipient C57BL/6J mice. In (A) bone marrow and (B) spleen GFP-mTRF2 
colocalizes with endogenous TRF1. GFP-mTRF2 was visualized by the GFP-tag, TRF1 was 
detected by a TRF1 specific antibody. Chromatin was counterstained with DAPI. White arrows 
indicate colocalization of endogenous TRF1 with recombinant GFP-mTRF2. 
Immunofluorescence, 63x1.25. 
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5.9. Tumor occurrence in TRF2 over-expressing C57BL/6J  
 recipient mice 
 
Tumor-development in all primary and secondary recipient C57BL/6J mice was 
investigated and documented throughout the course of the experiment. To be 
considered as a potential TRF2 related tumor, the individual mouse had to fulfill a 
set of defined criteria (Figure 11): 
I monitored a total of 152 mice, 30 mice were transduced with a GFP-control 
transgene and 122 mice were transduced with the TRF2 transgene. As the first 
criteria, only mice were considered that received bone marrow transduced with 
the TRF2 transgene. 
Then I screened all primary mice that received bone marrow potentially 
transduced with the TRF2 transgene to confirm integration. Secondary mTRF2 
and GFP-mTRF2 mice were considered to be positive since they received bone 
marrow from a successfully transduced and verified primary mouse. After 
genotyping by nested PCR I considered 95 mice out of the 122 mice for TRF2 
related tumor development.  
Since I assumed that TRF2 is interfering with the apoptosis cascade by inhibiting 
the ATM pathway, I considered previous results on ATM -/- and p53 -/- knock-out 
mouse models as a standard for the expected time to observe tumor 
development. ATM deficient mice develop thymic lymphomas at approximately 
two to four month of age [165] and p53 deficient mice show spontaneous 
development of a variety of neoplasms by six months of age [166]. I assumed a 
similar time frame for TRF2 and predicted initiation of tumor development at 
approximately 26 weeks after transplantation. It might be possible that my mouse 
model does not completely inactivate the apoptosis pathway and rather 
resembles a p53 +/- phenotype. To take this into account, I extended the time 
frame to 52 weeks. A total of nine out of the 95 mice died at an age of 52 weeks 
or earlier.  
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At last an individual mouse had to show macroscopical signs of tumor 
development to be considered. Eight out of the remaining nine mice were 
showing those signs, mainly a drastically enlarged thymus, spleen, liver, and 
kidneys. It is important to note that although an organ might look normal 
macroscopically, it may still possess tumor pathology. 
 
 
 
 
Figure 11 Applied criteria for the definition of TRF2 related tumor development. Four 
criteria were applied to determine if an occurring tumor might be related to the expression of 
transgenic TRF2. Only a total of eight tumors were eventually considered. One tumor was derived 
from a primary recipient and seven tumors from secondary recipients. p.t. - post transplantation; 
FD - found dead. 
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Taken together, I macroscopically observed potential TRF2 related tumor 
development in eight mice. One mouse was a primary recipient; the other seven 
mice were secondary recipient mice (Table 1). 
 
 
Table 1  Summary of potential TRF2 related tumors. (A) Background information of 
mice that potentially developed a TRF2 related tumor. (B) Macroscopical observations of organs 
from considered mice. FD - found dead. 
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5.10. Mouse Colony-Forming cell assay 
 
The potential of hematopoietic stem cells to produce heterogeneous populations 
of actively dividing hematopoietic progenitors, which proliferate and differentiate 
into mature blood cells, can also be observed in vitro.  Such an assay allows 
quantifying multi-potential progenitors and lineage-restricted progenitors of the 
erythroid, granulocytic, monocyte-macrophage, and megakaryocyte-myelopoietic 
pathways, as well as a subset of mouse pre-B lymphoid cells. When cultured in a 
suitable semi-solid matrix, individual progenitors, called colony-forming cells 
(CFCs), proliferate to form discrete cell clusters or colonies. 
To further investigate if TRF2 over-expression in hematopoietic stem cells can 
promote abnormal growth and differentiation patterns, I applied such a colony-
forming assay. For this particular experiment I isolated bone marrow from a 
primary recipient mouse, which received donor bone marrow successfully 
transduced with the GFP-mTRF2 transgene. To promote the growth of bone 
marrow erythroid progenitors (BFU-E and CFU-E), granulocyte-macrophage 
progenitors (CFU-GM), and pluripotent granulocyte-macrophage, erythroid and 
megakaryocyte progenitors (CFU-GEMM), I selected a media enriched with stem 
cell factors (SCF) and selected cytokines (IL-3 and IL-6). 
To overcome a potential low transduction rate, I performed flow cytometry to 
enrich the cell population for donor derived bone marrow cells that show a GFP-
signal from the GFP-tagged TRF2 recombinant protein (GFP-positive). In 
parallel, I also selected for bone marrow cells that were negative for GFP and 
therefore non-transduced (internal negative control). As an additional external 
negative control, I isolated bone marrow from a non-transplanted C57BL/6J 
mouse. 
For this experiment I decided to split the cells into a methylcellulose-based assay 
to investigate cell growth, as well as differentiation patterns, by fluorescent 
microscopy (5.10.1) and also into a liquid-based assay, which would permit 
subsequent flow cytometry analysis (5.10.2). 
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5.10.1. CFC Assay in MethoCult Media 
 
After three weeks in culture the CFCs in MethoCult media were analyzed using 
fluorescent microscopy. Although colonies formed in all three assays, the number 
of colonies in the GFP-positive assay was not different from the internal, GFP-
negative and the external, C57BL/6J negative control. Surprisingly, colonies from 
GFP-mTRF2 expressing cells, which were initially sorted for their GFP-signal, did 
not show any GFP-signal when analyzed by fluorescence microscopy.  
 
5.10.2. Liquid-based CFC Assay in M5300 Media 
 
Cells cultured in M5300 media for over two weeks were subsequently analyzed 
by flow cytometry (Figure 12). 
After two weeks in culture 19.9% cells in the GFP-positive assay did show a 
GFP-signal (A and B, top). Strikingly, 19.3% of cells positive for GFP were also 
positive for CD45.1 with a total rate of 85.9% CD45.1 positive cells in this assay. 
In contrast, cells from the C57BL/6J control and the GFP-negative assay only 
showed background levels for GFP (1.5% and 1.8%) and CD45.1 (4.6% and 
5.8%) (A and B, top). Thus, cells in the GFP-positive assay were successfully 
sorted for GFP-mTRF2 expression and a subset of cells maintained this 
expression over two weeks in culture. 
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Figure 12 Differentiation analysis on sorted bone marrow cells with respect to their 
over-expression of GFP-mTRF2. (A) GFP-mTRF2 expressing bone marrow was analyzed after 
two weeks in liquid culture by flow cytometry using a set of differentiation markers. As a negative 
control, bone marrow from the same mouse negative for GFP-mTRF2 and bone marrow from a 
C57BL/6J mouse were analyzed. (B) %-values in (A). (C) Same as (A), but sorting for CD11b 
positive cells in respect to the CD45.1 status. (D) %-values in (C). Red frames indicate 
differences in CD11b differentiation in the three compared populations (see 5.10.2 for details). 
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I then analyzed the levels of differentiation in each of the three assays with 
respect to their GFP-signal (A). I applied four different surface markers: CD3ε, 
CD11b, CD19 and CD34. Except for CD11b, I only measured marginal 
differences in the differentiation pattern in the presence of GFP-mTRF2 over-
expression (B). For CD11b, however, I scored a total of 19.7% of cells positive 
for this surface marker, compared to 3% in the C57BL/6J control assay and 3.4% 
in the GFP-negative assay. Surprisingly, the majority of cells positive for CD11b 
in the GFP-positive assay did not show a GFP-signal. To further investigate the 
origin of this CD11b positive population, I measured the levels of CD11b in 
respect to CD45.1 surface marker (C). Interestingly, all cells positive for CD11b 
had its origin in the CD45.1 donor bone marrow since they were positive for this 
surface marker (D). Taken together, these data suggest that cells sorted for a 
GFP-signal (from the GFP-mTRF2 expression) show a different differentiation 
pattern than GFP-negative control cells do. 
 
5.11. Induction of apoptosis in mice over-expressing TRF2 
 
To see how cells from mice over-expressing TRF2 in their hematopoietic system 
respond to DNA damage and if these cells are impaired in their ability to activate 
the ATM-dependent apoptosis pathway, I measured levels of apoptosis by flow 
cytometry (5.11.1) and confocal microscopy (5.11.2). 
Results  73 
5.11.1. Detection of irradiation induced apoptosis by Annexin V 
 
Annexin V is a marker for the early detection of apoptotic cells, which can be 
followed by flow cytometry. In normal cells the phospholipid phosphatidylserine 
(PS) is located on the inner leaflet of the plasma membrane. During the early 
stages of apoptosis, PS is translocated to the outer layer and is exposed on the 
external surface of the cell. This early event in apoptosis can be detected by 
using a sensitive method that detects PS exposure. Annexin V is a Ca2+-
dependent phospholipid binding protein. Although it can bind to a variety of 
phospholipids, it has highest affinity for phosphatidylserine (PS) [167], so when 
apoptosis initiates, Annexin V binding to the cell surface increases. To measure 
levels of apoptosis, I irradiated primary mice, which were positive for the 
integration of the mTRF2 transgene. As a positive control I chose either a 
C57BL/6J mouse or a primary GFP-control mouse. Mice were tested before and 
after irradiation and levels of apoptosis in thymocytes were measured by flow 
cytometry (Figure 13). Non-irradiated thymocytes from mice transduced with the 
mTRF2 transgene were showing 2.1% of apoptotic cells compared to 54.2% of 
apoptotic cells post irradiation. In contrast, thymocytes from a C57BL/6J control 
mouse were showing 2.6% apoptotic cells prior irradiation and 49% post 
irradiation (A). Next I repeated the experiment in mice over-expressing the GFP-
mTRF2 transgene compared to GFP-control mice. Non-irradiated thymocytes 
from mice transduced with the GFP-mTRF2 transgene were showing 1.1% of 
apoptotic cells compared to 46.3% of apoptotic cells post irradiation. In contrast, 
thymocytes from a GFP-control mouse were showing 5.1% apoptotic cells prior 
irradiation and 49.7% post irradiation (B). 
In my experiments thymocyte suspensions from mice over-expressing TRF2 do 
not show lower levels of apoptosis post irradiation. 
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Figure 13 Irradiation induced apoptosis in mice over-expressing mTRF2 and GFP-
mTRF2 measured by the percentage of Annexin V positive thymocytes using flow 
cytometry. (A) Percentage of apoptotic thymocytes in mice over-expressing mTRF2 compared to 
thymocytes from C57BL/6J control mice and (B) percentage of apoptotic thymocytes in mice 
over-expressing GFP-mTRF2 compared to thymocytes from GFP over-expressing mice, prior and 
post irradiation (IR) with 5 Gy. 
 
 
5.11.2. Detection of irradiation-induced apoptosis in individual 
  cells over-expressing TRF2 by confocal microscopy 
 
I stated above that whole thymocyte suspensions from mice over-expressing 
TRF2 do not show decreased levels of apoptosis compared to control mice, post 
irradiation. I whished to determine if this was only due to the low transduction 
rate with the TRF2 transgene, and individual cells over-expressing TRF2 might in 
fact be able to withstand irradiation-induced apoptosis. 
Therefore, I performed an immunodetection for the activated form of ATM with 
respect to the expression of GFP-mTRF2, on spleen tissue before and after 
irradiation (Figure 14). 
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Figure 14 Irradiation induced ATM activation in spleen from mice over-expressing 
GFP or GFP-mTRF2. (A and B) ATM activation in mice over-expressing GFP compared to (C 
and D) ATM activation in mice over-expressing GFP-mTRF2, prior and post irradiation (IR) with 5 
Gy. Phosphorylated ATM was detected using an antibody against the Serine-1981 
phosphorylation at ATM (ATM-pS1981). DNA was counterstained with DAPI. White squares show 
a magnified area of the tissue. Confocal image, 63x. 
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In spleen from a GFP-control mouse, irradiation activated ATM was not 
detectable prior to irradiation (A). As expected, ATM became activated by 
irradiation and was detectable in the majority of splenocytes (B). This result 
correlates with previous results from the Annexin V assay. Surprisingly, while a 
nuclear GFP-mTRF2 signal was detectable in a small number of splenocytes 
prior to irradiation (C), this nuclear pattern disappeared completely post 
irradiation. Instead I detected a rather non-specific GFP-signal coming from the 
cytoplasm of a small number of cells, which also show ATM activation (D). 
Together these observations confirm the results from the Annexin V assay and 
suggest that the over-expression of TRF2 in mice does not abrogate the 
activation of ATM upon irradiation. 
 
5.12. Western analysis of tumorigenic tissue for transgenic TRF2 
 
I observed tumor development in a number of secondary mice, which received 
bone marrow transduced with transgenic TRF2, and screened them for the over-
expression of TRF2 by Western analysis. While I investigated numerous tissues 
from tumorigenic mice, I did not observe TRF2 over-expression.  
Figure 15 shows a characteristic result for my Western analysis. Due to certain 
criteria (5.9) I considered some of the tumorigenic tissues as good candidates for 
being affected by a TRF2 related tumor. In parallel to the Western analysis I 
applied immunofluorescence on bone marrow and splenocytes from this 
individual mouse and found only a subset of cells that over-expressed GFP-
mTRF2 (Figure 10). 
Taken together, my Western and immunofluorescence analysis did not show any 
evidence of TRF2 over-expression in the observed tumor tissues. 
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Figure 15 Western analysis of spleen from a secondary recipient mouse, which 
expressed GFP-mTRF2 and died from a CD4/CD8-double-positive T-cell lymphoma. Protein 
samples were probed with an antibody against GFP, p53-pS15 (p53-P), ATM-pS1981 (ATM-P) 
and TRF2. γ-Tubulin (γ-Tub) was included as a loading control. As a negative control, a protein 
sample from a C57BL/6J control spleen was loaded. As a positive control, protein extract from 
HeLa 1.2.11 cells expressing GFP-mTRF2 was loaded. 
 
 
5.13. Genotyping for transgenic TRF2 integration in tumorigenic 
 tissue samples 
 
My previous results suggested that tumor development in mice transduced with 
TRF2 was independent from the over-expression of the transgene. However, I 
considered the possibility that TRF2 over-expression might be important for 
initiating tumor development, but dispensable, or even antagonistic, for further 
tumor growth and therefore may be silenced. In this case, the transgene should 
still be detectable within the genome of tumorigenic tissue. I genotyped a large 
number of collected tissue samples from primary and secondary recipient mice to 
screen for the TRF2 transgene (Figure 16 and Table 2). I also included tissue 
samples from primary and secondary GFP-control mice as internal negative 
controls. As a positive control I included genomic DNA of 3T3 cells transduced 
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with GFP-mTRF2 at a rate of 70%, 22% and 2%. This allowed for semi-
quantitative calculations on the transduction rate of the genomic samples. 
  
 
 
 
Figure 16 Genotyping for the integration of transgenic TRF2 in tissue samples from 
mice transduced with GFP, GFP-mTRF2 or mTRF2. GAPDH was selected as a positive PCR 
control. As a semi-quantitative transduction indicator (+), 3T3 cells were transduced with GFP-
mTRF2 at a rate of 70%, 22% and 2%. 'Mock' indicates genomic DNA from a C57BL/6J negative 
control mouse. (-) indicates a ddH2O negative control. Genomic DNA from GFP-control mice is 
labeled in green color, genomic DNA from potential TRF2 related tumors is labeled in red color. 
See Tab. 2 for a detailed legend. 
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Table 2  Origin of the genomic DNA used in genotyping assay in Figure 16. Genomic 
DNA from GFP-control mice is marked by a green background color, genomic DNA from potential 
TRF2 related tumors is marked by a red background color. LN - lymph node. 
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The genotyping results suggested that none of the screened genomic DNA 
contained traces of transgenic TRF2, and the observed tumors were not caused 
by the TRF2 transgene. 
 
5.14. Pathological observations on potential TRF2 related tumor 
 tissue 
 
Tissue sections of all potential TRF2 related tumors (5.9, Table 1) were also 
characterized by pathological analysis (Figure 17). 
I found that seven out of the eight mice showed a large cell, blastic T-cell 
lymphoma, involving liver, spleen and thymus. Spleen, liver and thymus were 
infiltrated and replaced by a diffuse monotonous neoplastic infiltrate composed of 
cells with large oval nuclei, with a delicate chromatin pattern, and scant 
cytoplasm. The cells had a brisk mitotic rate but characteristically had foci of 
apoptotic cells. The renal glomeruli displayed a thickening of the basement 
membrane and some were hyalinized (A). 
Another mouse (S1-GFP R2) showed signs of myeloid leukemia; the spleen was 
enlarged and replaced by immature myeloid cells and showed almost no 
lymphoid areas. The liver had several small clusters of myeloid cells. The kidney 
had extensive thickening of the glomerular basement membrane with many 
hyalinized glomeruli. There were infiltrates of plasma cells in the hilus and in 
cluster within the cortex (B). 
I found tumor development in mice that were transduced with the TRF2 
transgene and which developed these tumors within a timeframe of 52 weeks of 
age. The pathological observations furthermore suggested tumor development in 
organs that appeared macroscopically normal (compare Table 1 B versus Figure 
17 A and B). I cannot rule out that my macroscopical observations were 
insufficient to detect every potential TRF2 related tumor that occurred in the 
course of this project. 
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Figure 17 H&E - staining of tumor tissue. (A) Tissue samples from a secondary recipient 
mouse, which developed a large cell, blastic T-cell lymphoma, involving liver, spleen and thymus. 
Spleen, liver and thymus were infiltrated and replaced by a diffuse monotonous neoplastic 
infiltrate composed of cells with large oval nuclei with a delicate chromatin pattern and spare 
cytoplasm. The cells had a brisk mitotic rate but characteristically had foci of apoptotic cells. The 
renal glomeruli had thickening of the basement membrane and some were hyalinized. (B) Tissue 
samples from a primary recipient mouse, which developed myeloid leukemia in the course of the 
experiment. The spleen was enlarged and replaced by immature myeloid cells and was showing 
almost no lymphoid areas. The liver had several small clusters of myeloid cells. The kidney had 
extensive thickening of the glomerular basement membrane with many hyalinized glomeruli. 
There were infiltrates of plasma cells in the hilus and in cluster within the cortex. Both mice were 
successfully transduced with the TRF2 transgene. Staining was applied on sections of liver, 
thymus, spleen and kidney. The lower panels (C) show sections of control tissue from a healthy 
C57BL/6J mouse. 
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5.15. Characterization of T-cell lymphoma by flow cytometry 
 
To further characterize the T-cell lymphoma that developed in a larger group of 
mice transduced with the TRF2 transgene, I analyzed thymocytes that displayed 
pathological evidence of a T-cell lymphoma by flow cytometry (Figure 18). The 
figure shows a typical result for flow cytometric analysis. 
 
 
 
 
Figure 18 Flow cytometric analysis of thymoma material. The enlarged thymus of a 
secondary recipient mouse expressing GFP-mTRF2 was prepared for FACS analysis. As tumor 
markers CD4 and CD8 were used. The red frames indicate percentages (%) of CD4/CD8-double-
positive populations. The analysis suggests the presence of a donor derived CD4/CD8-double-
positive T-cell lymphoma, which is negative for GFP-mTRF2. 
 
  
I confirmed the presence of a CD4/CD8-double-positive T-cell lymphoma. A total 
of 97.2% of cells positive for CD45.1 were double-positive for CD4 and CD8. 
However, only 0.1% of all thymocytes in the assay were positive for GFP. 
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Thymocytes negative for CD45.1 were low in numbers and did not show any 
specific CD4/CD8 pattern. Thus, the observed CD4/CD8-double-positive T-cell 
lymphoma originated from the CD45.1 donor population but appeared not to be 
caused by the immediate over-expression of GFP-mTRF2. 
 
5.16. Analysis of pathological samples and metaphase spreads for 
 genome instability 
 
In the course of the project I observed tumor development in a number of mice. 
Despite being initially transduced with the TRF2 transgene, these tumors did not 
show evidence of current expression of the transgene. While an insufficient 
transduction rate with the transgene and TRF2 unrelated tumor development is 
one possibility, genome instability, as it is a hallmark of many tumors, might also 
lead to the loss of the TRF2 transgene. Therefore, I screened pathological 
samples of the T-cell lymphomas for anaphase bridges (Figure 19). 
 
 
 
 
Figure 19 Anaphase bridges in H&E - stained liver and spleen sections from a 
secondary recipient mouse carrying a CD4/CD8-double-positive T-cell lymphoma. The 
arrows point to the chromatin bridges between the separating chromosomes. A dashed line 
outlines normal anaphases displayed in the pictures to the very left. 
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Anaphase bridges are caused by the uncontrolled non-homologous end fusions 
of double-stranded breaks. This leads to new, randomly distributed breaks during 
mitosis when the fused chromosomes are pulled apart. As a result, further 
genome instability occurs, which eventually leads to the loss of genomic DNA. 
The occurrence of anaphase bridges in the investigated spleen and liver cells 
indicate genome instability. In addition to the presence of anaphase bridges I 
also found genome instability in metaphase spreads from the same tumors 
(Figure 20). The metaphase spreads displayed multiple telomere signals at 
telomeres as well as signs of polyploidy, both characteristics of genome 
instability. 
 
 
 
 
Figure 20 Genome instability was observed in metaphase spreads (MPS) prepared 
from splenocytes of a secondary recipient mouse carrying a CD4/CD8-double-positive T-
cell lymphoma. The telomeres were stained with a telomere specific probe conjugated to FITC 
(green). Chromatin was counterstained with DAPI. The arrows point to chromosome ends with 
multiple telomeres (see enlarged pictures). Immunofluorescence, 63x1.25. 
Discussion  85 
6. Discussion 
 
The telomeric repeat binding factor TRF2 is an important component of shelterin 
and it plays a central role in the protection of telomeres from the DNA damage 
machinery. The MRN subunit Mre11 is part of the DNA damage sensors of the 
ATM pathway [168-170] and as such it also associates with telomeres. TRF2 
appears to play a central role in preventing telomeres from activating ATM. The 
kinase ATM [171] acts as an important transducer of the DNA damage signal and 
requires autophosphorylation on S1981 to be activated. Phosphorylation of 
S1981 leads to concomitant dissociation into monomers, which is presumed to 
be the active form of the kinase [152]. Double-stranded breaks and other 
genome stress lead to a rapid conversion of the ATM pool into active ATM-
pS1981 monomers and, in turn, to the phosphorylation of regulators of the G1/S, 
intra-S, and G2/M cell cycle transitions [152]. Activation of ATM also takes place 
in response to telomere damage and, as shown recently, during the telomere 
replication process in late G2 [172]. In both cases the unprotected telomeres 
associate with phosphorylated ATM [173]. Furthermore, ATM targets become 
phosphorylated in aging cells with shortened telomeres [154]. There is also 
evidence for a role of ATM in the telomere damage pathway, which showed the 
diminished ability of ataxia telangiectasia (A-T) cells to mount a DNA damage 
response after telomere uncapping [173, 174]. However, several lines of 
evidence suggest that a second PIKK (phophatidylinositol 3-kinase-like kinase), 
such as ATR or DNA-PKcs, can transduce the telomere damage signal in the 
absence of ATM [173, 175]. 
As I described in the introduction, it is presumed that TRF2 is an important part of 
the shelterin complex and protects the telomeres from uncontrolled processing 
through the DNA damage machinery, most likely by hiding the 3’-overhang via 
strand-invasion into the duplex part of the telomeres. However, while hiding the 
3’-overhang in the T-loop structure, the T-loop displays structural features 
resembling DNA lesions, including single strand to double strand transitions, 3’ 
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and 5’ ends, and single-stranded DNA. Therefore, human telomeres may need 
additional mechanisms to circumvent checkpoint activation.  
The in vitro data that initiated this thesis work is based on experiments 
suggesting that the removal of TRF2 from the telomeres results in the localization 
of the activated, phosphorylated form of ATM to unprotected chromosome ends 
[173] and induces ATM-dependent apoptosis [174]. More recently it has been 
suggested that TRF2 protects telomeres through a direct interaction with ATM 
and blocks its activation.  
TRF2 binds ATM in a region surrounding S1981 and prevents its phosphorylation 
and inhibits the monomerization and activation of ATM. As a result, TRF2 
abrogates the downstream outcomes of the ATM dependent DNA damage 
response, including phosphorylation of various ATM downstream targets and cell 
cycle arrest [161]. Therefore, high concentrations of TRF2 at sites of telomeres 
protect telomeres from processing by the DNA damage machinery. Since TRF2 
appears to be abundant only at the sites of telomeres, this protection mechanism 
seems to be limited to telomeres. This could change if TRF2 is upregulated 
throughout the nucleus, e.g. by over-expression, in which case high levels of 
TRF2 could inhibit ATM and the DNA damage machinery also at other sites of 
the genome where double-stranded breaks need to be processed. As a result, 
these breaks could not be sufficiently processed and genome instability would 
occur. Thus, TRF2 would be a potent suppressor of the DNA damage machinery. 
In turn, in many tumor cells the ability to regulate checkpoints and to sufficiently 
process DNA damage is compromised. This is mainly due to mutations in genes 
in the ATM/p53 pathway, but also other checkpoint regulating tumor-suppressor 
proteins. It has been shown that patients suffering from A-T are estimated to 
have a 100-fold increased risk of cancer compared to the general population. 
Lymphoid cancers predominate in childhood, and epithelial cancers, including 
breast cancer, are seen in adults [176]. Considering that the inhibition of ATM by 
mutations has such a severe impact and results in a drastic development of 
tumors, it is intriguing to elucidate if the inhibition of ATM by over-expression of 
TRF2 can cause a similar tumorigenic phenotype. 
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ATM -/- mice displayed growth retardation, neurologic dysfunction, male and 
female infertility secondary to the absence of mature gametes, defects in T- 
lymphocyte maturation, and extreme sensitivity to irradiation. The majority of 
animals developed malignant thymic lymphomas between two and four months 
of age. Several chromosomal anomalies were detected in these tumors. 
Fibroblasts from these mice grew slowly and exhibited abnormal radiation-
induced G1 checkpoint function. ATM-disrupted mice resemble the ataxia 
telangiectasia phenotype in humans [165]. In addition, mutations in the p53 
tumor-suppressor gene, an ATM downstream target protein, are frequently 
observed genetic lesions in human cancers. p53 -/- mice appear normal but are 
prone to spontaneous development of a variety of neoplasms by six months of 
age [166]. 
I designed a mouse model in the course of this thesis work to investigate TRF2’s 
potential to act as an oncogene in vivo when over-expressed in the 
hematopoietic system. Based on the in vitro results and on previous mouse 
models for ATM and p53 deletions, I expected that the over-expression of TRF2 
will have an inhibitory effect on ATM throughout the nucleus and prevent the 
correct processing of randomly occurring DNA double-stranded breaks, which 
eventually leads to tumor formation. 
  
I started the project by designing two transgenic TRF2 constructs, which would 
allow the over-expression of TRF2 in the hematopoietic system of C57BL/6J 
mice. I cloned mTRF2 and GFP-mTRF2 into a lentiviral vector system and tested 
their functionality by transfection into murine 3T3 cells. My immunofluorescence 
data suggested functional expression of both transgenes in vitro. I further 
confirmed over-expression of both transgenes by Western analysis. Thus, I 
designed and verified two functional TRF2 expression systems, allowing the 
over-expression of TRF2 in murine cells in vitro. 
I then used the lentiviral backbone of the designed vector system to produce 
virus batches carrying both transgenes. The lentivirus was produced in 293T 
cells and the quality of each virus batch was validated in a p24 ELISA assay. For 
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the first virus batch, which I eventually used for the generation of the Primary #1 
mouse colony, I measured p24 values of 3x109 particles/ml for the mTRF2 
lentivirus and 8.5x109 particles/ml for the GFP-mTRF2 lentivirus. I considered 
both viral titers as adequate to sufficiently transduce hematopoietic stem cells 
from donor bone marrow.  
Next, I transduced donor bone marrow from CD45.1 and GFP donor mice with 
the corresponding lentivirus. By immunofluorescence and Western analysis I 
detected functional over-expression of both transgenes in murine bone marrow. I 
subsequently transplanted transduced bone marrow into irradiated C57BL/6J 
recipient mice, termed Primary #1, and monitored them for tumor development 
over time. 
To show engraftment of the transplanted bone marrow and the successful 
integration of the transgene into the hematopoietic system, I genotyped recipient 
mice four months after their transplantation. Although I detected the transgene in 
the majority of all recipient mice, the detection failed when I used just the outer 
primer pair of the nested PCR. This suggested a very low integration rate, 
possibly due to a lower viral titer than the p24 ELISA assay initially suggested. 
Although I believe that over-expression of TRF2 in hematopoietic cells in 
principal could promote tumor development despite a low transduction rate, it is 
desirable to see high transduction efficiency for a number of reasons. First, high 
transduction efficiency increases the chance of potential TRF2 related tumor 
development because more hematopoietic stem cells are expressing the 
transgene. Second, larger numbers of TRF2 over-expressing cells would allow 
the detection of early processes during tumor development in a small subset of 
cells by methods like flow cytometry or colony forming assays.      
I therefore decided to generate a second colony of recipient mice, termed 
Primary #2. The lentivirus production protocol was optimized to yield a high viral 
titer. By a p24 ELISA assay I measured values of 8.2x107 particles/ml for mTRF2 
and 6.4x108 particles/ml for GFP-mTRF2 for the new virus batches. In addition I 
included the production of a GFP-control lentivirus and measured for this virus a 
p24 ELISA value of 3.8x109 particles/ml. Although the p24 ELISA values in this 
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second production process were roughly tenfold lower then in the first lentivirus 
production process, I believe that this was influenced by the difference in the 
number of dead particles in the virus batches. 
For the generation of the Primary #2 colony I infected CD45.1 donor bone 
marrow and transplanted it into irradiated C57BL/6J recipient mice. Four months 
post transplantation, I genotyped the Primary #2 colony. Surprisingly, the number 
of mice positive for either transgenic mTRF2 or GFP-mTRF2 was lower than in 
the Primary #1 colony. Since I used the same nested PCR method to detect the 
presence of the transgene in both colonies, I concluded a less effective 
transduction of the donor bone marrow in the case of the Primary #2 colony. This 
would suggest that I did not effectively optimize the viral production. 
I realized at this point that a major challenge for this project was low transduction 
efficiency. Surprisingly, although I attempted to optimize the viral production, the 
optimization process had the opposite effect and led to lower transduction 
efficiency. To overcome the challenge of low transduction rates and to further 
promote tumor growth, I expanded bone marrow from primary recipient mice 
positive for transgenic TRF2 into secondary recipient mice. 
In the course of the project I followed a total of 122 mice potentially over-
expressing transgenic TRF2. While I observed tumor development in some of 
them, I applied a number of criteria to judge if the tumor could be related to TRF2 
over-expression. To be considered as a potential TRF2 related tumor, the 
individual mouse had to be positive for the TRF2 transgene. This was initially 
confirmed by the genotyping assay. The previous in vitro studies also suggested 
that over-expressed TRF2 interferes with the ATM pathways, thereby blocking 
downstream targets like p53 from being activated. It was observed that p53 -/- 
mice showed tumor development at approximately six month of age [166]. 
Considering the age of all mice at the time of transplantation (eight weeks) and 
the fact that the impact of the transgene might be weaker due to the low 
transduction efficiency, I considered only mice that were 52 weeks of age or 
younger when they showed signs of sickness. The final requirement for TRF2-
related tumorigenesis had to be the macroscopical observation of tumor 
Discussion  90 
development in these mice. Taken together, I observed potential TRF2 related 
tumor development in eight out of 122 mice. Among these eight mice was one 
primary recipient mouse; all other mice were secondary recipients. Interestingly, I 
discovered later into the project that the primary recipient mouse suffered from 
myeloid leukemia, while the seven secondary recipient mice suffered most likely 
from a large T-cell lymphoma. I confirmed for two out of the seven secondary 
mice a T-cell lymphoma based on pathological data and flow cytometry. A T-cell 
lymphoma is macroscopically characterized by an enlarged thymus. I observed 
tumor enlargement in all secondary recipient mice, which, by my criteria, may 
have developed a TRF2 related tumor. This finding suggested that T-cell 
lymphoma also developed in those secondary mice that were not pathologically 
analyzed. In contrast, I did not observe tumor development in any of the GFP-
control mice within 52 weeks of age. Thus, I detected an increase in T-cell tumor 
development in secondary recipient mice carrying transgenic TRF2. 
For my next approach to link over-expression of transgenic TRF2 with tumor 
development, I analyzed protein extracts from all potential TRF2 related tumor 
samples for the presence of the transgene by Western analysis. Surprisingly, I 
could not detect higher levels of TRF2 in any of the investigated tissues. I also 
screened for levels of activated ATM. Although I detected decreased levels of 
activated ATM in tumor samples, suggesting an inhibited ATM pathway, I did not 
see this result in all tumor samples. In parallel, when I analyzed tumorigenic 
tissue by fluorescence microscopy, expression of transgenic TRF2 was 
detectable only in a subset of cells. Therefore, my Western and 
immunofluorescence analysis did not provide further evidence for the correlation 
of tumor development, TRF2 over-expression and ATM inhibition. Consequently, 
when I analyzed tumorigenic tissue of a mouse transduced with the GFP-mTRF2 
transgene by flow cytometry I did not only confirm the presence of a CD4/CD8-
double-positive T-cell lymphoma, I also found that the majority of the lymphoma 
cells were negative for a GFP signal. This suggests again that transgenic TRF2 
is not the cause for the T-cell lymphoma development.  
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Because I detected an increase in tumor development independent of the actual 
expression of the potential transgene, I considered a temporal, early stage 
tumorigenic effect of the TRF2 transgene. I assumed that TRF2 over-expression 
would promote early stage tumor formation, but would then be no longer needed 
for further tumor growth or even have an antagonistic effect. TRF2 would 
therefore act through a “Hit & Run” mechanism. If TRF2 over-expression would 
be antagonistic to promote further tumor growth, gene silencing could facilitate 
the inhibition of further TRF2 over-expression. In this case, the transgenic TRF2 
expression would be inhibited on the protein level, but the presence of the 
transgene would be still detectable. Therefore, I analyzed a large number of 
genomic DNAs by genotyping for the presence of transgenic TRF2. I could not 
detect the presence of the TRF2 transgene in any of the samples, including 
genomic DNA isolated from T-cell lymphoma developing mice. This result 
suggests that the TRF2 transgene is not present in the developed T-cell 
lymphoma. I propose two possibilities: either the transgene was never expressed 
in the individual mice and tumor development occurred without TRF2 over-
expression, or the TRF2 transgene was disrupted and could not be detected by 
genotyping. 
Disruption of genomic information can be caused by genome instability, which is 
often a hallmark of cancer. Genome instability is characterized by chromosome-
fusions. In anaphase this appears as chromatin bridges and eventually leads to 
chromosome breaks, inevitably leading to genome disruption and loss of 
genomic information. To determine the presence of genome instability in the T-
cell lymphomas, I screened the pathological specimens for anaphase bridges. 
Indeed, the investigated T-cell lymphomas were characterized by brisk mitotic 
rates and did show numerous anaphase bridges. Although I cannot rule out that 
tumor development occurred independently from the TRF2 transgene, this result 
may suggest that the transgene was deleted by genome instability. 
Instead of linking tumor development to a transgene post tumor occurrence, I 
also wondered if I could show TRF2’s oncogenic potential in healthy tissue, by 
performing a colony-forming assay (CFA). Therefore, I isolated bone marrow 
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from an individual GFP-mTRF2 over-expressing mouse, sorted the cells into 
GFP-negative and GFP-positive, and grew them in a CFA and also in a liquid 
assay. Although I did detect more colony growth in the GFP-positive compared to 
the GFP-negative CFA over time, the numbers were not significantly different. 
However, when I analyzed the liquid assay by flow cytometry, I detected an 
increase in the population of CD11b cells within the assay sorted for GFP-
positive cells compared to GFP-negative cells. Although I initially sorted for GFP-
positive cells, the increase in CD11b positive cells emerged from the CD45.1 
population, but it no longer showed a GFP-signal. I conclude from this result that 
the initial expression of GFP-mTRF2 in bone marrow cells appears to influence 
the differentiation pattern over time. However, I cannot explain why the GFP-
signal was lost. I am also aware that I investigated only one individual mouse and 
further quantitative analysis is needed to support my results. 
I knew from the previous studies on TRF2 that it has the potential to inhibit ATM 
in vitro. If a cell enters apoptosis, this is frequently connected to ATM, which is a 
key player in the apoptosis pathway. Apoptosis can be induced by irradiation and 
this induction should fail in an organism where the apoptosis pathway is 
abrogated due to a lack of ATM activity. Therefore, I predicted that mice over-
expressing TRF2 in their hematopoietic system should show signs of apoptosis 
inhibition. To measure apoptosis in situ I used flow cytometry to measure levels 
of the early apoptosis marker Annexin V in thymocytes before and after 
irradiation and compared the results to GFP-control mice. However, TRF2 over-
expressing mice did not show any difference in the levels of apoptosis after 
irradiation compared to GFP-control mice. 
Taking the previous results of this study into consideration, a number of reasons 
could account for the outcome of this experiment. TRF2 might be unable to 
inhibit ATM in vivo and in vitro results may not be transferable to a mouse model. 
More likely, the low transduction rate by transgene-containing virus led to only a 
subset of cells over-expressing TRF2 and these cells would show an abrogated 
apoptosis pathway. To investigate further, I checked individual cells over-
expressing TRF2 for the presence of ATM-pS1981 after irradiation using 
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confocal microscopy. While I found cells over-expressing TRF2 before irradiation, 
these cells were lost after irradiation. In addition, cells negative for transgenic 
TRF2 showed normal activation of ATM, confirming the Annexin V results. I do 
not have an explanation for the loss of transgenic TRF2 over-expression, but one 
could speculate that TRF2 over-expressing cells are very sensible to irradiation. 
Summarizing the results of this thesis work so far, I observed a small increase in 
tumor development in mice that were transduced with transgenic TRF2 
compared to control mice, although I could not show the actual over-expression 
of the transgene in an established tumor by fluorescent microscopy or flow 
cytometry. These findings suggest that TRF2 is not a strong oncogene. First, I 
successfully transduced the hematopoietic system of recipient mice with 
transgenic TRF2 and detected functional expression of recombinant TRF2 in the 
mouse model. The observed TRF2 over-expression, however, was only 
detectable in a small subset of cells, which probably diminished the potential 
tumor phenotype, but did not abrogate it. In fact, I did see a slight increase in the 
development of CD4/CD8-double-positive T-cell lymphomas in secondary 
recipient mice. It is important to mention that I see these tumors in independent 
secondary colonies and I can therefore rule out clonal tumors. The 
transplantation of TRF2 over-expressing bone marrow from one primary recipient 
into multiple secondary recipients should have increased the chance of a TRF2 
related tumor development. The observation that a small increase in CD4/CD8-
double-positive T-cell lymphomas was detected and that I did not see tumor 
development in the control mice, initially proposed that transgenic TRF2 leads to 
the tumor development. However, since transgenic TRF2 was not presently 
expressed in the observed tumors, and even more surprisingly, no genomic 
evidence of the transgene was detectable, a deletion of the transgene might 
have occurred post tumor initiation. Again, this could suggest that TRF2 has an 
antagonistic effect on the very same tumor it initiated. Once it initiated tumor 
development, it might hinder further tumor growth. The genome instability I 
observed in the developed tumor cells could result in the loss of the TRF2 
transgene. 
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A loss of the transgenic TRF2 signal was also observed upon irradiation and 
subsequent confocal analysis, which suggests that cells over-expressing TRF2 
are highly unstable. Irradiation induces double-stranded breaks and in a healthy 
cell, the ATM pathway usually responses to these types of damage. However, 
assuming TRF2 abrogates the ATM pathway, double-stranded breaks will not be 
processed and will lead to genome instability and eventually cause the loss of the 
TRF2 transgene. However, this is only a theoretical possibility and unlikely to 
happen in actual cells and there are more reasonable explanations why TRF2 
was not detectable in the tumor tissue. 
In these studies I also observed a potential impact of the TRF2 transgene on the 
differentiation pattern. I could see by flow cytometry that bone marrow cells 
sorted for the expression of recombinant TRF2 differentiated differently over time 
than untransduced cells from the very same bone marrow, in particular I saw an 
increase in the CD11b positive cell population. However, it is inaccurate to call 
this differentiation pattern significant since it was only observed in bone marrow 
derived from one individual mouse. 
When I measured the CD4/CD8-double-positive T-cell lymphomas by flow 
cytometry, I observed that the tumors were not expressing the TRF2 transgene. 
This might suggest spontaneous development of T-cell lymphomas, although 
irradiation could be ruled out as the reason, because the tumors were donor 
derived and donor cells were not irradiated. 
Finally, I did not see a specific correlation for the activation of ATM in the 
observed tumors. Western analysis detected ATM activation in tumorigenic 
tissue, but not in all investigated T-cell lymphomas. Due to the lack of over-
expression of recombinant TRF2 in these lymphomas it is difficult to make a 
connection between ATM inhibition and TRF2 over-expression. 
 
To determine if TRF2 can act as an oncogene in the mouse hematopoietic 
system, I used lentiviral technology to deliver the transgene. This method allows 
the study of a transgene explicitly during the hematopoiesis. However, if I were to 
repeat the study, I would partially change the setup of my technical approach. I 
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consider the sufficient transduction of the hematopoietic system with the TRF2 
transgene as the integral part of my studies. As mentioned before, I did 
experience a very low transduction rate of the hematopoietic system for the 
TRF2 transgene. A high transduction rate of the donor bone marrow would be in 
a repetition of the study a primary target. To overcome potentially low 
transduction rates I would, in addition to optimizing the viral titer, enrich TRF2-
positive cells by flow cytometry either before transplantation or after 
transplantation. Subsequently I would transplant the enriched TRF2-positive cells 
into recipient mice. This method would guarantee a higher transduction rate and 
would make it easier to answer some of my questions, e.g. is the TRF2 
transgene lost due to genome instability? However, the technical approach 
should be sufficient to determine if the TRF2 transgene is a strong oncogene. In 
this case, a single tumorigenic TRF2 over-expressing cell would automatically 
expand to a clonal tumor. 
 
In parallel to my work, another group provided results arguing that TRF2 is a 
potent oncogene when over-expressed in C57BL/6J mice [177, 178]. This group 
knocked-in transgenic TRF2 under the control of a bovine keratin K5 promoter 
and the generated mice were therefore termed K5TRF2. This promoter targets 
TRF2 to basal cells and stem cells of the epidermis. As a result these mice have 
a severe light-sensitivity such as premature skin deterioration, hyperpigmentation 
and increased incidence of skin tumors. Furthermore these mice are more 
susceptible to UV-induced skin carcinogenesis, similar to mice deficient in 
components of the NER pathway. The researchers in this study claimed that the 
transgenic TRF2 mice showed an increased susceptibility to develop skin tumors 
and suggested a role of TRF2 in skin tumorigenesis. They furthermore proposed 
that the XPF nuclease, a component of the NER pathway and also localized to 
telomeres, is largely responsible for the telomere degradation associated with 
TRF2 over-expression. According to these results the researchers suggested 
that the interaction between TRF2 and XPF increases XPF activity at telomeres, 
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leading to XPF-dependent telomere loss. In turn, TRF2 may deregulate NER at 
non-telomeric DNA lesions resulting in increased sensitivity to UV-damage. In a 
later study from the same group, the researchers presented data suggesting that 
TRF2’s role as an oncogene is exaggerated in the absence of telomerase. To 
show that, they used mice expressing TRF2 under the control of a K5 promoter, 
but in this study the observed mice were negative for the catalytic subunit of 
telomerase in mice, TERC (K5TRF2/TERC-/- mice). In their studies telomerase 
deficiency dramatically accelerates TRF2-induced epithelial carcinogenesis in 
telomerase deficient mice expressing TRF2. Their data also showed a 
dramatically accelerated TRF2-induced epithelial carcinogenesis in the absence 
of telomerase, coinciding with increased chromosomal instability and DNA 
damage. They also observed an increase in telomere recombination, suggesting 
that TRF2 favors the activation of alternative telomere maintenance mechanisms. 
Finally, the researchers claimed in their model that the DNA damage response 
was not compromised. Levels of activation of ATM, Chk2, and p53 accumulation 
were normal in the observed K5TRF2/TERC-/- tumors. 
Other groups have previously reported increased levels of TRF2 mRNA in 
human multistep hepatocarcinogenesis as well as in gastric carcinomas [179, 
180]. Interestingly, these groups observed an inverse correlation of levels of 
TRF2, and other telomere proteins like TRF1 and TIN2 [180], and telomere 
length. They suggested that increased protein levels of TRF2 and other telomeric 
proteins prevent the access of telomerase and inhibit telomere elongation. As a 
result, telomere crisis is induced and promotes tumor development. 
 
In principle, my approach is not comparable with the one described above. 
Instead of over-expressing the TRF2 transgene in basal cells and stem cells of 
the epidermis, I targeted the hematopoietic system of mice. In the alternative 
strategy, the effect of TRF2 over-expression in the skin depends on the presence 
of XPF, and is largely enhanced by UV-induced damage. Considering the 
proposed in vitro results for TRF2 over-expression [161], I assumed that 
increased levels of TRF2 alter the DNA damage machinery, due to the inhibition 
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of ATM, and promote the accumulation of unrepaired DNA double-stranded 
breaks, which eventually leads to the development of tumors within the 
hematopoietic system. Although I see an increase in the development of 
CD4/CD8-double-positive T-cell lymphomas, the actual over-expression of TRF2 
is not detectable in these tumors.  
FISH results also did not show the loss of telomere signals. Although FISH is not 
a quantitative tool to measure telomere length, the complete loss of signal of any 
given telomere can be detected by this method. I did, however, detect the 
presence of genome instability by the presence of anaphase bridges, double-
telomeric signals at a number of telomere ends, and by polyploidy, all of which 
are hallmarks of cancer. With regard to previous results and considering that I 
over-expressed TRF2 in a telomerase positive background, I suggest that the 
increase of genome instability in mice over-expressing TRF2 in basal cells and 
stem cells of the epidermis in the absence of telomerase is mainly a hallmark of 
cancer, but not due to the over-expression of TRF2 per se. However, I cannot 
rule out the additive effect of TRF2 and XPF with UV-damage leads to additional 
genome instability. My hematopoietic TRF2 model is not suitable for studies 
investigating the impact of UV-light. 
Neither tumors derived from K5TRF2/TERC-/- mice or the tumors observed in my 
experiments showed tempered activation of components of the DNA damage 
machinery. Activation of ATM and p53 was observed in these tumors, although 
not always. This suggests that the tumorigenic effect of TRF2 does not inhibit 
ATM by a direct interaction. 
The impact of telomerase deficiency on tumor development in mice has been 
discussed elsewhere [181]. It has been found that mice lacking telomerase in an 
ATM-deficient background have a lower rate of tumorigenic translocations and 
tumor formation. Initial studies on the impact of over-expressed TRF2 [182] in 
primary human fibroblasts with a compromised apoptosis pathway also revealed 
that TRF2 lowers the occurrence of telomere fusions and overall genome 
instability. These two studies suggest that over-expression of TRF2 stabilizes 
short telomeres and inhibits genome instability rather than promote tumor 
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formation. That, however, could change if over-expressed TRF2 has an 
enhanced effect together with UV-damage and other telomere factors, like XPF. 
In this case, TRF2 is actually protecting the telomeres from a damage response 
by inhibiting the access of the DNA damage machinery. As another effect it 
promotes the activity of factors like XPF. Since telomere fusions require the prior 
removal of the 3’-overhang, a probable function of XPF, increased XPF activity 
might lead to more telomere fusions.  Again, taking all known results into 
account, TRF2 over-expression should rather stabilize short telomeres and 
decrease the number of telomere fusions and overall genome instability. Or, if it 
is a potent oncogene, its effect should be indirect by compromising the proper 
function of the DNA damage machinery via ATM inhibition. 
Based on my results I suggest that TRF2 is not, if at all, a strong oncogene. I did 
observe over-expression of TRF2 in the hematopoietic system but I did not find 
tumor development in combination with an acute over-expression of TRF2 within 
the tumor. Although I did observe genome instability, I do consider this as an 
indication of cancer rather than an effect of TRF2 over-expression. Therefore I 
am also positive that TRF2 did not get lost after tumor initiation due to genome 
instability. As mentioned previously, genome instability in cells is not promoted by 
over-expressing TRF2 [182]. I also think that it is difficult to draw a connection 
between upregulation of TRF2 mRNA levels in tumor tissue and actual protein 
levels of TRF2. It is important to measure the actual presence of TRF2 protein at 
the telomeres, as this is the prominent area where the protein carries out its main 
function. I also suggest that the effect of TRF2 over-expression, as observed in 
K5TRF2 mice, is caused by the pure abundance of TRF2 at the telomeres. It has 
been shown that the shelterin complex is composed of six different proteins. Any 
imbalance on the protein level, as caused by over-expression, within this 
complex might disturb the proper function of shelterin. But depending on the 
choice of the promoter used to over-express a transgene, strong over-expression 
might artificially disrupt the shelterin complex. In the case of K5TRF2 mice it 
could be that the artificial increase of TRF2 is compromising the function of the 
other shelterin subunits, thereby disrupting the telomere complex and causing 
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dysfunctional telomeres. Of course, it is possible that this might define the 
oncogenic potential of TRF2, meaning if TRF2 is highly over-expressed, it will 
disrupt the shelterin complex, cause telomere dysfunction, genome instability, 
and tumor formation. However, it has only been shown that TRF2 mRNA levels 
are upregulated, in addition to TRF1 and POT1 mRNA levels [180], but to which 
extent the actual TRF2 protein contributes to that is not known. In my 
experiments, strong over-expression of TRF2 did not cause a significant increase 
in the development of tumors and I did not observe over-expression of TRF2 in 
the investigated CD4/CD8-double-positive T-cell lymphomas. Therefore, I 
suggest that TRF2 is not a dominant oncogene in the mouse hematopoietic 
system.
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